|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
12/2013 | Recent | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/13Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 12/26/2013 > 198 patent applications in 112 patent subcategories. patent applications/inventions, industry category
20130343987 - Myocardial perfusion imaging methods and compositions: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.... Agent: Gilead Sciences, Inc.
20130343988 - Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treament of cancer: The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer.... Agent: Exelixis, Inc.
20130343989 - Methods and compositions related to internalizing rgd peptides: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed... Agent: Sanford-burnham Medical Research Institute
20130343990 - Radiolabelled octreotate analogues as pet tracers: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention... Agent: Ge Healthcare Limited
20130343991 - Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer: Methods and compositions utilizing ether and alkyl phospholipid ether analog compounds for treating cancer and imaging, monitoring, and detecting cancer stem cells in humans.... Agent: Cellectar, Inc.
20130343994 - Cholinesterase inhibitors: The invention provides compounds that inhibit cholinesterases, such as acetylcholinesterase and butyrylcholinesterase. Such compounds are useful to prevent or treat exposure of a patient (e.g., a human) to an organophosphoric nerve agent (e.g., sarin and VX) or to treat a patient suffering from a neurodegenerative disorder such as Alzheimer's Disease... Agent: The University Of Montana
20130343993 - Radiolabeled 5-ht6 ligands: Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by 5-HT6 receptor ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as 5-HT6 positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), methods for using such... Agent: Abbvie Inc.
20130343992 - Radiolabeled pde10a ligands: Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds... Agent: Abbvie Inc.
20130343995 - Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy: Novel methods of synthesis of ethylenedicysteine-sugar conjugates and therapeutic and diagnostic applications of such conjugates are disclosed. Methods of synthesizing these conjugates in high purity are also presented as using starting materials such as thiazolidine carboxylic acid. Also disclosed are methods of imaging, treating and diagnosing disease in a subject... Agent:
20130343996 - Graphite-coated magnetic nanoparticles: The present invention relates to graphite-coated magnetic nanoparticles, methods for the synthesis of graphite-coated magnetic nanoparticles, and methods of using graphite-coated magnetic nanoparticles for targeted delivery of siRNA-based therapy, as multimodal imaging probes and for hyperthermia cancer treatment.... Agent: Rutgers, The State University Of New Jersey
20130343997 - Metal coating of rare earth nano-phosphors and uses thereof: Core-shell nanoparticles comprises a phosphorescent core and metal shell comprising at least two metals The phosphorescent core may comprise an up converting phosphor. The phosphorescent core may comprise a trivalent rare earth cation. The phosphorescent core further may comprise a monovalent alkali metal. The phosphorescent core may optionally comprises a... Agent: The Regents Of The University Of California
20130343998 - Control and characterization of memory function: Provided herein are devices and methods for reversibly controlling memory function in living non-human animals. Some variations of methods for affecting memory function comprise temporarily inhibiting neurons of the hippocampus (e.g., neurons of the dorsal CA1 field of the hippocampus) during the acquisition or retrieval of a memory. Alternatively or... Agent: The Board Of Trustees Of The Leland Stanford Junior University.
20130343999 - Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions... Agent: Celsense, Inc.
20130344000 - Treatment of cognitive impairment in a subject with a neurological autoimmune disease: Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment.... Agent: The Johns Hopkins University
20130344004 - Matrix metalloprotease targeting nucleic acids: A reporter conjugate for non-invasive detection (e.g., imaging) of matrix metalloprotease (MMP) gene expression in vivo is disclosed. The conjugate includes a targeting nucleic acid linked to a contrast agent, such as a paramagnetic label that can be used with magnetic resonance (MR) imaging. The targeting nucleic acid can be... Agent: The General Hospital Corporation
20130344003 - Immuno-therapy for cancer treatment using iron oxide nanoparticles: An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor. Once the composition has been administered, it is recommended to avoid any means that would cause direct cytotoxic effects to the... Agent:
20130344001 - Indocyanine green-containing particles, photoacoustic-imaging contrast agent including the same, and method for producing the indocyanine green-containing particles: Indocyanine green-containing particles each include a metal oxide particle or a metal particle and an aggregate of indocyanine green. The aggregate of indocyanine green has a relative maximum absorbance at 880 nm or more and 910 nm or less.... Agent:
20130344002 - Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology: A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue.... Agent: Endocyte, Inc.
20130344005 - Bolus for treating hypocalcaemia in ruminants: The subject of the invention is a veterinary product or a nutrition product intended in particular for the prevention and treatment of hypocalcaemia in ruminant animals. The product is in the form of a bolus comprising calcium carbonate and calcium formate. Advantageously, two of these boluses are concomitantly administered, one... Agent:
20130344006 - Hair treatment compositions: A hair treatment composition comprising an acrylic pressure sensitive adhesive consisting essentially of a random copolymers comprising: i) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl acrylate or 2-ethylhexyl acrylate) and; ii) a short side-chain acrylic such as methyl acrylate; the weight ratio of C1-C6... Agent:
20130344007 - Frankincense chewing gum: This disclosure relates to a composition that may include frankincense resin and various combinations of essential oils, which combinations may be effective in promoting weight loss. The present disclosure further relates to a weight loss and satiation composition that may include frankincense resin and a flavorant. In some embodiments, the... Agent: Yl Holdings, Inc.
20130344009 - Foaming oral care formulation and system and method of forming and using same: Oral care compositions, systems, and methods of using and forming the compositions and systems are disclosed. The composition includes a surfactant and/or a foaming agent to cause the composition to foam prior to administration to an oral cavity. The foaming composition readily and quickly reaches interstitial areas within the oral... Agent:
20130344008 - Noncarious material and anticarious agent containing rare sugar: To provide a composition for preventing periodontal diseases (prophylactic agent of periodontal diseases), the composition having an excellent cariostatic property, being safe and stable for prolonged use and having less effects on flavor. A non-cariogenic material prepared by blending a rare sugar in the D form as selected from the... Agent: Matsutani Chemical Industry Co., Ltd.
20130344010 - Oral health improving compositions: The present invention is concerned with microorganisms or fragments thereof as sensorically neutral oral care agents, particularly for prevention of dental calculus, as anti-caries agents and/or anti-oral malodor agents. The invention is furthermore concerned with compositions comprising microorganisms or fragments thereof for reducing mutans Streptococci. Such compositions can be used... Agent: Basf Se
20130344011 - Reduction of tooth staining derived from cationic antimicrobials: Examples of cationic antimicrobial agent include quaternary ammonium compounds such as cetylpyridinium chloride, cetyl pyridinium fluoride, tetradecylpyridinium chloride, N-tetradecyl-4-ethyl pyridinium chloride and domiphen bromide; chlorhexidine; and metal ion sources to supply metal ions such as stannous, zinc or copper.... Agent:
20130344012 - Natural oil metathesis compositions and methods: A metathesized natural oil composition comprising (i) a mixture olefins and/or esters, or (ii) a metathesized natural oil, is disclosed. The metathesized natural oil composition has a number average molecular weight in the range from about 100 g/mol to about 150,000 g/mol, a weight average molecular weight in the range... Agent:
20130344013 - Water-in-oil emulsified sunscreen cosmetic: m
20130344015 - Aqueous fluid photoprotective compositions comprising tertiary-amine-terminated polyamide polymers: (b) at least one tertiary-amide-terminated polyamide (ATPA) polymer, formulated into a topically applicable, cosmetically acceptable aqueous support therefor; the subject anti-sun/sunscreen compositions are especially provided as sprays, notably for the purpose of increasing the sun protection factor (SPF) and/or of reducing or even eliminating the fluffing effect thereof.... Agent: L'oreal
20130344014 - Therapeutic vitamin d sun-protecting formulations and methods for their use: The present invention concerns topical sun-protecting formulations including therapeutically effective amounts of Vitamin D, including formulations that provide Vitamin D in bioavailable amounts that correspond to decreased natural Vitamin D production resulting from the sun-blocking effects of the formulations and formulations for the prevention and treatment of disorders and disease... Agent: Avidas Pharmaceuticals LLC
20130344016 - Method and apparatus for applying solid paint to skin: An apparatus for applying solid paint to the skin includes a housing having opposite first and second ends, a first quantity of solid paint in a first receptacle, a second quantity of solid paint in a second receptacle, and an actuator for longitudinally shifting the first receptacle relative to the... Agent: Dead Down Wind, LLC
20130344018 - Cosmetic composition comprising a particular zinc salt and a starch: The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one non-nitrogenous zinc salt and at least one starch, in a weight ratio of the amount of starch to the amount of zinc element ranging from 0.01 to 20. Another subject of the invention... Agent: L'oreal
20130344017 - Hair treatment composition: A hair treatment composition comprising: i) an oligosaccharide comprising 3 to 7 sugar units in which the linkage group between the sugar units is an a 1-4 link; and ii) an acrylic pressure sensitive adhesive comprising: i) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl... Agent:
20130344019 - Acrylic polymer: The present invention relates to acrylic emulsion polymers as well as to their use in hair care preparations such as in particular in hair styling preparations.... Agent: DsmIPAssets B.v.
20130344020 - Hair styling composition: A hair treatment composition comprising: i) a polyacrylate cross polymer; and ii) an acrylic pressure sensitive adhesive comprising: a) an acrylic group having a side-chain with at least 4 carbons (eg n-butyl acrylate or 2-ethylhexyl acrylate) and; b) a short side-chain acrylic such as methyl acrylate.... Agent:
20130344022 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Living Proof, Inc.
20130344023 - Polymer-active agent conjugates: A polymer includes at least one monomeric unit represented by Formula I, II, or III: where X is CH2 or O; R1 is H, COOR2, COCH3, CONHR2, OR2 or SR2; L is a bond or a linker group; AA is a group derived from an active agent; each R2 is... Agent: Flex-biomedical
20130344024 - Co-therapy for diabetic conditions: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting... Agent: Daiichi Sankyo, Inc.
20130344026 - Dimeric smac mimetics: The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and... Agent:
20130344025 - Method for the administration of ligands, agonists of ligands of the tnf family with reduced toxicity: The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family... Agent: Apoxis S. A.
20130344027 - Multi-functional polymeric materials and their uses: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle... Agent: University Of Tennessee Research Foundation
20130344028 - 1'-substituted carba-nucleoside analogs for antiviral treatment: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.... Agent:
20130344029 - Macrocyclic inhibitors of flaviviridae viruses: o
20130344030 - Macrocyclic inhibitors of flaviviridae viruses:
20130344031 - Substituted pyrrolo-pyrazole derivatives as kinase inhibitors: Compounds represented by formula (Ia) or (Ib) and wherein R and R1 are as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.... Agent: Nerviano Medical Sciences S.r.l.
20130344032 - Method of treating anemia caused by ribavirin treatment of hepatitis c using erythropoietin alpha: Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It... Agent:
20130344033 - Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs): The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or... Agent: Institut National De La Recherche Agronomique (inra)
20130344041 - Genetically modified muscle cells which express neurotrophic factors: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a... Agent: Ramot At Tel-aviv University
20130344040 - Process for the preparation of a composition of genetically modified hematopoietic progenitor cells: Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene... Agent: Johnson & Johnson Research Pty. Limited
20130344039 - Th1-associated micrornas and their use for tumor immunotherapy: Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype.... Agent:
20130344042 - Dietary management of celiac disease and food allergy: The present disclosure provides compositions and methods for dietary management of celiac disease and food allergy in a subject, such as a formula-fed infant, via enteral administration of an effective amount of at least one hydrolyzed protein and Lactobacillus rhamnosus GG (LGG). The inventive nutritional compositions may contain a hydrolyzed... Agent:
20130344043 - Method for enhancing ppary expression: The present invention provides a method for enhancing PPARγ expression, comprising administering a subject in need thereof an effective amount of Lactobacillus gasseri PM-A0005, which was deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC), China with Deposition No. M 207039.... Agent:
20130344045 - Nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms: The present invention provides a nutritional composition that is suitable to reduce the impact of stress on intestinal symptoms and/or conditions. The composition comprises one or more selected from a probiotic microorganism,one or more inactive probiotic, and one or more culture medium of one or more probiotic; and soluble fiber,... Agent: Nestec S.a.
20130344044 - Probiotics in a pre- and/or post-surgical environment: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the... Agent: Nestec S.a.
20130344046 - Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.... Agent:
20130344034 - Parovirus having a cpg-enriched genome useful for cancer therapy: A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus... Agent: Deutsches Krebsforschungszentrum Stiftung Des Oeff
20130344038 - Method for enhancing engraftment of haematopoetic stem cells: The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G... Agent:
20130344035 - Methods of using regenerative cells in the treatment of renal diseases and disorders: Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a... Agent:
20130344036 - Plant derived cell culture material: The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials... Agent: Upm-kymmene Corporation
20130344037 - Treatment of inflammatory diseases using placental stem cells: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.... Agent: Anthrogenesis Corporation
20130344047 - Methods and composition for treating heart failure and ischemia: Methods and compositions for treating heart failure by administration of beneficial agents to the heart.... Agent: Abbott Cardiovascular Systems, Inc.
20130344051 - Compostion of matter for treating or preventing various types of cancer and neoplastic diseases in a mammal: A composition of matter can reduce size of cancerous tumors in mammals. The composition of matter comprises Bromelain infused with vitamin C creating a protein enzyme complex which can be administered in an effective amount to reduce the size of cancerous tumors in mammals.... Agent: Garfield Medical Group
20130344050 - Glycopegylated factor ix: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a... Agent: Novo Nordisk A/s
20130344048 - Method of reducing insulin resistance by administering a hyaluronan-degrading enzyme: Provided herein are methods of reducing or ameliorating insulin resistant using a hyaluronan-degrading enzyme, and in particular a hyaluronan-degrading enzyme that is conjugated to a polymer. The methods also can be used to prevent or ameliorate diseases and conditions associated with insulin resistance, such as cardiovascular disease and type 2... Agent:
20130344049 - Methods for treatment of ocular diseases: Methods and therapeutic treatments of ocular diseases are provided including applying peg-Arginase I to affected eyes. Methods are provided that simultaneously treat inflammation and neovascularization of eyes while promoting healing. Methods are provided to treat lesions or infections of an eye.... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
20130344052 - Peg-modified arginine/lysine oxidoreductase: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol, a production method thereof, and methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.... Agent:
20130344053 - Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides: The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof,... Agent: University Of Rochester
20130344054 - Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity: Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein are variant, recombinant β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type β-glucocerebrosidase. Further described herein are variant, recombinant β-glucocerebrosidase proteins that can have amino acid variations... Agent: Callidus Biopharama, Inc.
20130344055 - Antimicrobial agents: The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from... Agent: Lysando Ag
20130344056 - Keratin biomaterials for treatment of ischemia: Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns.... Agent: Wake Forest University Health Sciences
20130344057 - Binding molecules: The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of... Agent: Erasmus University Medical Center
20130344064 - Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof: The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies. More specifically, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties comprising a heavy chain variable region, a light chain, variable region, a human light chain constant region and a... Agent:
20130344065 - Combination treatment with vegf-c antagonists: The invention relates to a method and kit for treating cancer in a human subject, the method comprising administering to the subject in combination therapeutically effective amounts of a VEGF-C antagonist and an anti-neoplastic composition, and the kit comprising a VEGF-C antagonist for administering to the subject in combination with... Agent: Vegenics Pty Ltd
20130344063 - Diagnosing and monitoring cns malignancies using microrna: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.... Agent: The Brigham And Women's Hospital, Inc.
20130344062 - Identification and treatment of aggressive lung cancer tumors: This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step... Agent:
20130344059 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20130344060 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20130344058 - Monoclonal antibodies against dengue and other viruses with deletion in fc region: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the... Agent: The U.s. As Represented By The Secretary, Department Of Health & Human Services
20130344061 - Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).... Agent: Infinity Pharmaceuticals, Inc.
20130344067 - Alk1 receptor and ligand antagonists and uses thereof: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates... Agent: Acceleron Pharma, Inc.
20130344066 - Methods of monitoring conditions by sequence analysis: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the... Agent: Sequenta, Inc.
20130344070 - Antigen binding proteins that bind ccr2: There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and... Agent:
20130344069 - Antigen binding proteins that bind igf1r: There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments and derivatives of such antibodies, and IGF1R-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and... Agent:
20130344068 - Methods of preventing inflammation and treating pain using anti-ngf compositions: This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the... Agent:
20130344072 - Anti-vegf-c antibodies and methods using same: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.... Agent: Genentech, Inc.
20130344071 - Class i anti-cea antibodies and uses thereof: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR... Agent:
20130344073 - Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease,... Agent:
20130344074 - Uses of a dual v region antibody-like protein: Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region.... Agent: Sanofi
20130344076 - Antibody conjugates against variant nfkbib and uses thereof: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific... Agent: Viventia Bio Inc.
20130344079 - Compositions and methods for diagnosing and treating phenylketonuria (pku): A method of diagnosing Phenylketonuria (PKU) in a subject in need thereof is disclosed. The method comprises detecting phenylalanine fibrils in a tissue of the subject, wherein a presence or level above a predetermined threshold of said phenylalanine fibrils in said tissue, is indicative of PKU in the subject. Antibodies... Agent: Ramot At Tel-aviv University Ltd.
20130344078 - Emp2 antibodies and their therapeutic uses: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which... Agent: The Regents Of The University Of California
20130344077 - Monoclonal antibodies: The invention provides heterochimeric antibodies and/or fragments thereof comprising (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region sequences wholly or substantially corresponding to sequences found in antibodies from a target species which is different from the donor species;... Agent:
20130344075 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Vasgene Therapeutics, Inc.
20130344080 - Pilr alpha interactions and methods of modifying same: Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders.... Agent: Genentech, Inc.
20130344081 - Method of treating amyotrophic lateral sclerosis: Solution: The present invention provides an ALS treatment method that improves clinical symptoms of ALS or suppresses the progression of ALS by administering an anti-TNFalfa monoclonal antibody to an ALS patient; an anti-ALS drug containing an anti-TNFalfa monoclonal antibody; an anti-TNFalfa monoclonal antibody for use as an anti-ALS drug; and... Agent: The University Of Tokushima
20130344085 - Anti-pcsk9 antibodies, formulations, dosing, and methods of use: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.... Agent:
20130344084 - Cell culture methods to reduce acidic species: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.... Agent: Abbvie Inc.
20130344082 - Methods of treating or preventing periodontitis and diseases associated with periodontitis: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.... Agent:
20130344083 - Modulation of histone h2b monoubiquitination and treatment of cancer: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues... Agent:
20130344086 - Stable and soluble antibodies: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in... Agent: Esbatech, An Alcon Biomedical Research Unit LLC
20130344089 - Anti oligomer antibodies and uses thereof: The present invention relates to antibodies and antibody fragments specific for the toxic prefibrillar aggregates of amyloid-beta peptides, and uses thereof, for example in the diagnosis and treatment of amyloid diseases such as Alzheimer's disease and related disorders. The invention further provides methods for the identification of compounds potentially useful... Agent: Alzinova Ab
20130344090 - Antibodies against tissue factor pathway inhibitor (tfpi): The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.... Agent: Novo Nordisk A/s
20130344088 - Antibody formulation: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.... Agent:
20130344087 - Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors: Methods for administering combinations of compositions comprising anti-S1P antibodies or antibody fragments and modulators of sphingolipid metabolic pathway enzymes are described. Such methods allow aberrant or undesirable levels of S1P to be reduced in patients known or suspected to have a disease or disorder correlated with aberrant S1P levels, and... Agent:
20130344091 - Compositions and methods for increasing muscle growth: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.... Agent: Novartis Ag
20130344092 - Methods of using anti-thymocyte globulin and related agents: Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-β are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at... Agent: Genzyme Corporation
20130344093 - Anti-egfr antibodies and uses thereof: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth... Agent:
20130344094 - Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as... Agent:
20130344095 - Method of using cd1d over-expression in human dendritic cells to enhance cd8+ t cell-based and invariant natural killer t cell-based antitumor immunity: The manipulation of human dendritic cells (DCs) to induce potent anti-tumor immunity remains an essential subject of study. Here we report that the overexpression of CD1d in human DCs can enhance the priming of naïve CD8+ T cells against tumor antigen. We showed that CD1d can be overexpressed in the... Agent:
20130344096 - Histidyl-trna synthetases for treating autoimmune and inflammatory diseases: The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.... Agent: Atyr Pharma, Inc.
20130344097 - Ras mutation and compositions and methods related thereto: Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations.... Agent: Globeimmune, Inc.
20130344098 - Cat allergen conjugates and uses thereof: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is... Agent: Cytos Biotechnology Ag
20130344101 - B7-1-pe40kdel exotoxin fusion gene-based dna vaccine and the use thereof: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic... Agent: Affiliated Hospital Of Academy Of Military Medical Sciences, Pla
20130344099 - Fusion protein for secretory protein expression: There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the... Agent: Abera Bioscience Ab
20130344100 - Virus like particle production in plants: A method of producing a virus like particle (VLP) in a plant, and compositions comprising VLPs, are provided. The method involves introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a chimeric nucleotide sequence encoding, in series, an ectodomain from a virus trimeric... Agent: Medicago Inc.
20130344102 - Formulation: The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.... Agent:
20130344103 - Conjugation process: The present invention relates to a process for conjugation of an antigen.... Agent: Glaxosmithkline Biologicals S.a.
20130344104 - Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine: The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium difficile glycopolymer PS-II and a protein carrier. More specifically, the oligosaccharide is the hexasaccharide having the following formula (I) wherein R is a linker or spacer group. In... Agent:
20130344105 - Method for augmenting the immunogenicity of an antigen: The present invention relates to a method for augmenting the immunogenicity of an antigen in a mammal, comprising immunizing the mammal with a composition comprising the antigen, and an adjuvant in an amount of effective to augment the immunogenicity of said antigen, wherein the adjuvant comprises a Ling-Zhi-8 (LZ-8) protein.... Agent:
20130344106 - Methods and compositions for improving immune response by a nutraceutical antioxidant: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and... Agent:
20130344107 - Virus like particle purification: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.... Agent:
20130344108 - Inactivated poliovaccine: The invention provides an attenuated polio virus having a 5′ non-coding region consisting of the 5′ non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of the base pairs in stems... Agent: The Secretary Of State For Health
20130344109 - Immunogenic compositions: The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion,... Agent: Sanofi Pasteur Limited
20130344110 - Compositions and methods to elicit immune responses against pathogenic organisms using yeast-based vaccines: Embodiments of the present invention illustrate methods of treating and preventing infection due to a pathogen such as a fungal pathogen. In particular, the present invention relates to compositions and methods for vaccinations against or treatment for a fungal organism in a non-immunocompromised or immunocompromised subject.... Agent: Globeimmune, Inc.
20130344111 - Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies: A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, alone or in combination with another anti-cancer therapy. The method... Agent: Biodesix, Inc.
20130344112 - Detection of an immune response: Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a Th2a subset of CD4+ T cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of CD4+... Agent: Benaroya Research Institute
20130344114 - Composition for repairing cartilage tissue and method for making the same: A composition for repairing cartilage tissues includes a scaffold and a plurality of endothelial progenitor cells. The endothelial progenitor cells adhere on the scaffold. A method of making the composition for repairing cartilage tissue is also disclosed. This is advantageous for safely and quickly repairing cartilage tissues by using the... Agent:
20130344113 - Iron fortified food product and additive: The present invention relates to a food product which has been fortified in iron content, comprising a Fe3O4 sphere. The present invention also relates to an iron-containing additive for use in the above food product, in the form of a Fe3O4 sphere. The present invention further relates to a method... Agent: Magqu Co. Ltd.
20130344119 - Method for inducing in vivo migration of stem cell: The present invention relates to an implantable composition for treating a damaged tissue and a method for inducing an in vivo migration of a cell for treatment to a damaged tissue region. The present invention treats the damaged tissue by inducing/promoting homing of a cell for tissue generation by implanting... Agent: Tego Science Inc
20130344115 - Method for repairing and proliferating cartilage tissue and method of cartilage defect treatment: A method for repairing cartilage tissues includes the following steps: adhering a plurality of endothelial progenitor cells onto a scaffold to form a composition, and implanting the composition into an individual. The present invention also provides a method of cartilage defect treatment and a method for proliferating the cartilage tissues.... Agent:
20130344118 - Nanoparticle fabrication methods, systems, and materials: Nanosized particles are molded from granules of organic substances in nano-scale molds. The nano-scale molds can be fabricated from non-wetting, low surface energy polymeric materials. The nanosized particles can be virtually any shape, are typically less than 500 micrometers in a broadest dimension, and can include pharmaceutical compositions, biologic drugs,... Agent:
20130344116 - Oral particle consisting of an amorphous structure and a submicron domain: The present invention relates to compositions and methods of the preparation of an oral particle essentially consisting of an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property. The desired ratio of the amorphous structure to... Agent: Magnifica Inc.
20130344117 - Pegylated polyplexes for polynucleotide delivery: The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are provided. The invention further provides methods of using said polymers and polyplexes.... Agent: Intezyne Technologies, Inc
20130344121 - Cosmetic composition for make-up containing silicone elastomer: Disclosed is an elastic make-up cosmetic composition containing a silicone elastomer. More particularly, the make-up cosmetic composition includes a powder type silicone elastomer, powder extender pigment, hydrocarbon gel, anhydrous silicone oil and organic dispersant oil. A silicone elastomer of a surface-treated powder type and a polymer are used to improve... Agent: Cosmax Co., Ltd.
20130344120 - Mouth rinse emulsions: s
20130344122 - Nonwoven materials containing chlorhexidine acetate and triclosan: This invention provides medical articles having antimicrobial efficacy and good barrier properties. In particular, the medical articles comprise a nonwoven material and a coating comprising chlorhexidine acetate and triclosan.... Agent:
20130344123 - Use of silver-containing layers at implant surfaces: The disclosure relates to coatings that contain silver, either in the form of metallic silver, silver oxides, salts of silver, or combinations of these. The silver is present in a microparticulate or nanoparticulate form, which exerts antimicrobial activity when bacteria (e.g., in a body fluid) contact the coated surface. The... Agent: Rowan University
20130344124 - Agent for virus inactivation: An agent for virus inactivation capable of exhibiting inactivation action based on structural destruction such as degradation and decomposition against viruses, which comprises a monovalent copper compound such as cuprous oxide, cuprous sulfide, cuprous iodide, and cuprous chloride as an active ingredient, and a virus inactivation material, which contains the... Agent: The University Of Tokyo
20130344125 - Drug delivery device: The invention provides an implantable intracranial device for the site-specific delivery of a pharmaceutically active agent to a human or animal for treating a mental or neurological disorder, such as Alzheimer's disease, schizophrenia or other psychoses. The biodegradable device includes a pharmaceutically active agent for treating the disorder, polymeric nano-lipoparticles... Agent:
20130344126 - Bioerodable poly(etheresteramides) and medical article uses: Bioerodable poly(etheresteramides) and matrices formed therefrom, such as medical device coatings, are described. The matrices show desirable erosion properties desirable for therapeutic use. The matrices can include a bioactive agent which can be used to treat medical conditions.... Agent:
20130344127 - Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized... Agent: Biodelivery Sciences Interntional, Inc.
20130344128 - Method for treating ocular demodex: The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a compositions comprising a therapeutically effective amount of a substance chosen from at least one of... Agent: Tissuetech, Inc.
20130344129 - Inflammation-regulating compositions and methods: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally,... Agent: Carnegie Mellon University
20130344130 - Smart, self-decontaminating polymer and method for inhibiting the growth of a bacteria and fungus: A smart antimicrobial material and dressing to inhibit microbial growth is provided. Endogenous chemicals, such as metabolites produced from bacteria are utilized as chemical substrates and converted by enzymes to produce a disinfecting compound that will in turn inhibit the targeted microorganism. The material shall remain passive until such time... Agent:
20130344131 - Hemostatic devices: Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate... Agent:
20130344136 - Composition comprising diamine oxidase for the prevention of hangover symptoms: The present invention refers to a composition comprising diamine oxidase (DAO) for use in the prevention of hangover symptoms produced by the consumption of alcoholic drinks.... Agent: Dr Healthcare Espana, S.l.
20130344137 - Functional foods comprising diamine oxidase and uses thereof: The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures.... Agent: Dr Healthcare Espana, S.l.
20130344133 - In vivo delivery of nucleic acids to the liver or liver tissue: The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell.... Agent: Veritas Bio, LLC
20130344134 - Inhibitors of cyclic amp phosphodiesterases: Recombinant fission yeast cells and methods of using them are described, which provide for identification of chemical and biological inhibitors or activators of a target exogenous phosphodiesterase (PDE). The invention provides, in some aspects, compounds that inhibit cAMP PDE activity and compositions that include such compounds. The invention, in part,... Agent: Trustees Of Boston College
20130344139 - Method of reducing contact lens intolerance with non-drying antihistamines: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method is useful in treating dry eye diseases. The method is also useful in reducing contact lens intolerance in the eyes. The method comprises administering to... Agent:
20130344138 - Methods of treatment for solid tumors: m
20130344135 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically... Agent:
20130344132 - Sustained-release liposomal anesthetic compositions: The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection... Agent: Pacira Pharmaceuticals, Inc.
20130344140 - Novel pharmaceutical combinations and methods for treating cancer: Methods of selectively targeting a p53-deficient cancer cell, comprising administering to a patient suffering from cancer (i) a reversible cell cycle arrest-inducing agent for inducing cell cycle arrest in a p53-positive cell; and (ii) an aurora kinase inhibitor, wherein said reversible cell cycle arrest-inducing agent is administered prior to administration... Agent: Agency For Science, Technology And Research
20130344141 - Concentration and mental performance amplifying formulation: A concentration and mental performance amplifying formulation comprising rhodiola rosea and geranium oil, together with at least one of vinpocetine, phosphatidylcholine, caffeine and Salix alba (White Willow Bark). In another aspect, there is disclosed a concentration and mental performance amplifying formulation comprising: rhodiola rosea, geranium oil, and at least one... Agent:
20130344142 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both... Agent:
20130344143 - Formulations of nonopioid and confined opioid analgesics: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably... Agent:
20130344146 - Dry formulations of aripiprazole: The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition.... Agent: Teva Pharmaceutical Industries Ltd.
20130344144 - Low flush niacin formulation: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.... Agent: Abbvie Inc.
20130344145 - Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof: A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive... Agent: Posi Visionary Solutions LLP
20130344148 - Oral composition: The present invention relates to a tablet composition comprising a particle and a pharmaceutically acceptable carrier, wherein the particle comprises an amorphous structure and a submicron domain, and wherein the amorphous structure is a molecular solid dispersion of a drug in a polymeric matrix and the submicron domain is a... Agent: Magnifica Inc.
20130344149 - Oral dosage forms for modified release comprising tasocitinib: The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms.... Agent: Ratiopharm Gmbh
20130344150 - Direct compression tablets of otilonium: This invention is related to direct compression of otilonium or its pharmaceutically acceptable salt having perfect powder flowability, good tablet weight distribution and no sticking to the punches.... Agent:
20130344151 - Solid pharmaceutical composition comprising telithromycin: The invention relates to a novel solid pharmaceutical composition of telithromycin which facilitates swallowing by the patient.... Agent: Aventis Pharma S.a.
20130344153 - Method for reducing incidence or rate of development of skin cancers and related conditions: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of... Agent:
20130344152 - Peroxide dispersions: The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may... Agent: Arkema Inc.
20130344154 - Immortal unipotent porcine picm-19h and picm-19b stem cell lines: Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line. The unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. The growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions,... Agent:
20130344155 - Fenofibrate formulation: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first... Agent: Mylan, Inc.
20130344156 - Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.... Agent: Vectura Limited
20130344157 - Enhancement of the efficacy of therapeutic proteins: A formulation for administration of at least one therapeutic mammalian protein to a mammal or a protein selected from the group, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, comprising at least one therapeutic mammalian protein in... Agent: North-west University
20130344160 - Implantable bio-resorbable polymer charged with fragile macromolecules: The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH2═CR1)CO—K wherein: —K represents O-Z or NH-Z, Z representing (CR2R3)m—CH3, (CH2—CH2—O)m—H, (CH2—CH2—O)m—CH3, (CH2)m—NR4R5 with m representing an integer from 1 to 30; —R1,... Agent: Centre National De La Recherche Scientifique
20130344159 - Implantable swellable bio-resorbable polymer: The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2═CR1)CO—K (1) wherein: K represents O—Z or NH—Z, Z representing (CR2R3)m-CH3, (CH2—CH2—O)m-H, (CH2—CH2—O)m-CH3, (CH2)m-NR4R5 with m representing an integer from 1 to 30; R1, R2, R3, R4 and R5 independently... Agent: Centre National De La Recherche Scientifique
20130344158 - Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.... Agent: Bind Therapeutics, Inc.
20130344161 - Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions... Agent: Histogen, Inc.
20130344162 - Micronized placental tissue compositions and methods of making and using the same: Described herein are composition composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.... Agent:
20130344163 - Umbilical cord products: Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.... Agent:
20130344164 - Personal care products containing rainwater: This invention relates generally to formulations and methods for improving level of moisture absorption and retention by the skin and for improving the appearance, feel, or comfort of the skin, wherein the formulations comprise pure rainwater. In another embodiment of the invention, the formulations comprise a combination of natural extracts.... Agent: P.v. Creations
20130344165 - Jab1 inhibitory compositions for ossification and methods related thereto: This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement... Agent: Emory University
20130344166 - Topical mixture and method for dermal application to remove excess iron and other heavy metals from cellular tissue: A topical mixture intended to reduce undesirable Iron levels in the cells to optimize Mitochondrial functioning. A method of reducing undesirable levels of Iron in the cells to optimize Mitochondrial functioning.... Agent:
20130344167 - Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods: The present invention relates to a galenic composition suitable for administration to a non-human animal, including at least the following three components: one or more active principles; an agent for accelerating delitescence; an agent for delaying delitescence, wherein the agent for accelerating delitescence an the agent for delaying delitescence are... Agent: Vetalis Sarl
20130344168 - Compositions and methods apc, creb, and bad pathways to assess and affect cancer: Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway); and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway); and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose,... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.
20130344169 - Gene signature for the prediction of radiation therapy response: Described are mathematical models and method, e.g., computer-implemented methods, for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor.... Agent: University Of South Florida
20130344170 - Polymorphisms predictive of anthracycline- induced cardiotoxicity: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more... Agent: The University Of British Columbia
20130344171 - Acidic dialysis concentrate: The precursor of an acidic dialysis concentrate is characterized in that two separately provided partial concentrates are formed from the constituents of the acidic dialysis concentrate, wherein only the one partial concentrate contains glucose, preferably glucose monohydrate, while the other partial concentrate comprises other constituents needed for the acidic dialysis... Agent:
20130344172 - Antimicrobial acid formulation: An antimicrobial acid formulation for food and farm applications includes an aqueous solution comprising sulfuric acid present in the aqueous solution in a quantity of from about 1% to about 45% by weight and at least one buffering sulfate salt present in the aqueous solution in a quantity of from... Agent: Advanced Food Technologies, LLC
20130344174 - Bioactive fractions and compounds from polygonum genus, their use in anti-diarrhea and the method of preparation: The present invention discloses the utility of factions and compounds from Polygonum chinense Linn in anti-diarrhea. The invention also includes their preparation and application method for anti-diarrhea treatment.... Agent: Hong Kong Baptist University
20130344176 - Methods and compositions for treatment of add/adhd, depression, memory problems and other conditions: Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.... Agent:
20130344173 - Modulating disease through genetic engineering of plants: In certain embodiments transgenic plants (e.g., transgenic tomatoes) are provided that comprise cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where the peptide has biological activity (e.g., lowers SAA, and/or increases paroxonase activity, and/or improves... Agent: The Regents Of The University Of California
20130344175 - Preparation used for anti-tachyarrhythmia and its preparation method: A kind of Corydalis extract for anti-tachyarrhythmia, the extract prepared by the following method: Corydalis crude powder 100 parts by weight, is extracted by 60-80% ethanol 600-1000 parts by volume in 1-3 times, combined filtrate, concentrated under reduced pressure to a fluidextract of the relative density of 0.2-0.5 g/mL; take... Agent:
20130344177 - Weight loss beverage: A beverage composition for promoting weight loss, the beverage including a stimulant agent, a fat burning agent, a carbohydrate blocking agent, an anti-cholesterol agent, an insulin sensitizing agent, a sweetening agent, an aromatic agent, an antioxidant agent, an anti-inflammatory agent, a dietary agent, and an diuretic agent. The present invention... Agent: Yl Holdings, Inc.
20130344179 - Anti-fatigue composition: The present invention relates to a food supplement composition for reducing fatigue, and/or improving recovery and resistance to fatigue. The composition comprised of collagen hydrolysate, blueberry extract and liquorice extract.... Agent:
20130344178 - Natural shampoo using herbal medicine mature decoction having a function of preventing hair loss and stimulating hair growth, and method of preparing the same: A natural shampoo is provided. The natural shampoo is made using a herbal medicine mature decoction which is obtained by putting herbs including lotus roots, lotus leaves, red ginseng, Hippophae rhamnoides leaves and trunk, persimmon leaves, thuja orientalis, ginger, rosemary, black beans, black sesame, aloe, mulberry leaves, Orostachys japonicus, Angelica... Agent:
20130344180 - Weight loss and satiation composition: Weight loss compositions and systems are disclosed that may include various combinations of essential oils and other components, which may be effective in promoting weight loss. Some implementations may include a fat blocker, a filler component, an insulin sensitizer, and a fat growth suppressant. In some instances, the fat blocker... Agent: Yl Holdings, Inc.
20130344183 - Novel compound isolated from kaempferia pandurata roxb and use thereof as antiviral agent: The present invention relates to a novel compound isolated from Kaempferia pandurata Roxb and the use thereof as an antiviral agent. The compound isolated from Kaempferia pandurata Roxb shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent.... Agent: Konkuk University Industrial Cooperation Corp.
20130344182 - Novel use of panduratin derivatives or an extract of boesenbergia pandurata for promoting muscle mass growth, fighting fatigue, and enhancing exercise performance capability: The present invention relates to the novel use of panduratin derivatives or an extract of Boesenbergia pandurata for enhancing muscle mass growth, fighting fatigue and enhancing exercise performance. A panduratin derivative or a salt thereof or an extract of Boesenbergia pandurata of the present invention may be used without side... Agent: Biocare Co., Ltd.
20130344184 - Materials and methods for treatment and diagnosis of disorders associated with oxidative stress: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. The subject invention... Agent: Therapeutic Research LLC12/19/2013 > 217 patent applications in 105 patent subcategories. patent applications/inventions, industry category
20130336882 - Adhesive composition for soft tissues, adhesive composition for wound dressing or wound dressing composition: The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a... Agent: Mitsui Chemicals, Inc.
20130336883 - Deoxycytidine kinase binding compounds: The invention provides compounds that bind to deoxycytidine kinase (dCK) and compositions including pharmaceutically acceptable compositions containing the compounds. The compounds are useful in treating diseases and disorders where dCK activity is implicated such as cancer and immune disorders. The compounds also find use in clinical methodologies including positron emission... Agent: The Regents Of The University Of California
20130336881 - Method and device for accurate dispensing of radioactivity: A method of delivering a radioactive liquid, includes, performing an initialization, including; extracting at least a first amount of a radioactive liquid from a source of radioactive liquid, measuring a radioactivity level for the first amount of radioactive liquid, and performing a calibration phase. The calibration phase includes, extracting a... Agent: Universitat Zurich
20130336880 - Methods for in vivo identification of cancer initiating cells by multimodality reporter gene imaging: The present invention relates to a method for detecting cancer initiating cells in living animal body by multimodality reporter gene imaging. In the method of this invention, cells escaping from cell loss during tumor enlargement are identified as cancer initiating cells.... Agent:
20130336884 - Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells: A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of... Agent: The University Of North Carolina At Chapel Hill
20130336885 - Anti-lgr5 antibodies and immunoconjugates: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.... Agent: Genentech Inc.
20130336886 - Tumor specific antibodies and uses therefor: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or... Agent: Unc-charlotte
20130336887 - Compounds and methods for enzyme-mediated tumor imaging and therapy: The invention provides methods and compositions, e.g., for tumor imaging and therapy.... Agent: President And Fellows Of Harvard College
20130336888 - Psma-targeted dendrimers: A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such... Agent: Molecular Insight Pharmaceuticals
20130336890 - Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system: This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers by 18F labelling of such precursors.... Agent: Piramal Imaging Sa
20130336889 - Nanoparticle and method for detecting or treating a tumor using the same: A nanoparticle for detecting or treating a tumor is provided. The nanoparticle includes a plurality of polymer backbones and at least one first detectable substance, of which each of the polymer backbones includes a hydrophobic region, a hydrophilic region and a chelating region, and the first detectable substance is bound... Agent: National Taiwan University
20130336891 - Formulation of acoustically activatable particles having low vaporization energy and methods for using same: Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one... Agent: The University Of North Carolina At Chapel Hill
20130336892 - Chimeric t1r taste receptor polypeptides and nucleic acid sequences encoding and cell lines that express said chimeric t1r polypeptides: The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet... Agent: Senomyx, Inc.
20130336897 - Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio): Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) in their lysosomes. The amount of USPIO loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal. Both fixed macrophages and activated macrophages associated with inflammatory diseases and cancer phagocytize USPIOs, and... Agent:
20130336898 - Process for preparing a pharmaceutical formulation of contrast agents: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being... Agent: Guerbet
20130336893 - Exedin-4 peptide analogues: The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.... Agent: Sanofi
20130336894 - Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP... Agent:
20130336895 - Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology: A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue.... Agent: Endocyte, Inc.
20130336899 - Antimicrobial formulations that aid in wound healing: The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides,... Agent: Purdue Research Foundation
20130336900 - Voc-free compressed gas aerosol compositions: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a... Agent:
20130336901 - Flavorant ester salts of polycarboxylic acids and methods for immobilizing and delivering flavorants containing hydroxyl groups: Compositions are provided which contain immobilized flavorants for flavor delivery. In particular, smoking compositions are provided which contain flavorant ester salts of polycarboxylic acids.... Agent: Philip Morris Usa Inc.
20130336905 - Compositions of enhanced viscosity, clarity, or both enhanced viscosity and clarity: Provided herein are compositions that exhibit enhanced clarity, higher viscosity, or both enhanced clarity and higher viscosity for a wide range of application arts, such as personal care compositions. The compositions have lightly- to moderately-crosslinked PVP and at least one additive.... Agent: Isp Investments Inc.
20130336907 - High viscosity heat-treated xanthan gum: The present invention is directed to heat treated xanthan gums, which have improved solution viscosity over other xanthan gums heat-treated under the same processing conditions while maintaining the improved ease of use and the short, non-stringy gel texture of heat treated xanthan gums. Such high solution viscosity xanthan gums are... Agent: Akzo Nobel N.v.
20130336906 - Method of improving the appearance of aging skin: A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and carob fruit extract in combination to a target area of skin that exhibits a sign of aging skin. The composition is applied for a period of time sufficient to improve... Agent:
20130336904 - Novel anti-ageing peptides modulating survivin and compositions including same: The present invention relates to peptide compounds of the general formula (I) R1-(AA)n-X1-X2-Arg-Glu-Met-Asn-Trp-X3-(AA)P-R2 modulating the survivin protein. Furthermore, the present invention relates to a cosmetic or pharmaceutical composition, including at least one peptide of the general formula (I), in a physiologically acceptable medium as well as to the use thereof... Agent: Isp Investments Inc.
20130336909 - Personal care and health care compositions: The present invention relates to health care and personal care compositions comprising a silicone acrylate hybrid composition and at least one health care and/or personal care ingredient. Such compositions tend to provide desirable characteristics for the care and conditioning of hair and skin.... Agent: Dow Corning Corporation
20130336902 - Personal care compositions comprising a di-amido gellant and methods of using: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one... Agent:
20130336903 - Personal care compositions comprising a ph tuneable gellant and methods of using: wherein R5 is an aminofunctional moiety; L2 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L2 or R5 comprises a pH-sensitive group; and mixtures of [I] and [II]. The personal care composition may take a variety of forms such as a... Agent:
20130336908 - Sunscreen cosmetic composition: Provided is a sunscreen cosmetic composition that effectively protects from both UVA and UVB, has moist and cool feeling on use as well as excellent stability, and is able to form a film having a good ultraviolet protection effect when applied to skin. An oil-in-water sunscreen cosmetic composition comprising: (a)... Agent: Shiseido Company, Ltd.
20130336912 - Antiperspirant/deodorant compositions: Disclosed are new and improved antiperspirant/deodorant compositions and methods of reducing perspiration, where the new and improved antiperspirant/deodorant compositions contain a water dispersible organic polymer and can reduce the concentration of active antiperspirant ingredients while maintaining antiperspirant efficacy.... Agent:
20130336911 - Moc compositions: s
20130336910 - Olfactory receptors involved in the perception of sweat carboxylic acids and the use thereof: The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis... Agent: Chemcom S.a.
20130336913 - Hair care compositions and methods of treating hair: The present invention provides compositions, kits and methods for treating scalp hair. The compositions include fluorinated (but not perfluorinated), non-polymeric compounds in a suitable excipient to provide beneficial effects on hair.... Agent: Living Proof, Inc.
20130336914 - Malodor control compositions having activated alkenes and methods thereof: A malodor control composition having activated alkenes and methods thereof are provided. In some embodiments, a catalyst is provided in the composition. The composition is suitable for a variety of applications, including use in fabric and air freshening products.... Agent:
20130336915 - Particulate constructs for release of active agents: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.... Agent:
20130336916 - Botanical insecticides: The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C5H8)n, and its derivatives and analogs thereof, as active insecticidal ingredients; certain botanical... Agent:
20130336917 - Polymeric treatment compositions: Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.... Agent:
20130336918 - Compounds and methods for inhibiting phosphate transport: m
20130336919 - Compounds and methods for inhibiting phosphate transport:
20130336920 - Compounds and methods for inhibiting phosphate transport:
20130336921 - Compounds and methods for inhibiting phosphate transport:
20130336922 - Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.... Agent: Immatics Biotechnologies Gmbh
20130336923 - Carbonic anhydrase ix (g250) antibodies and methods of use thereof: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally... Agent: Dana-farber Cancer Institute, Inc.
20130336925 - Fusion polypeptides comprising mucin-domain polypeptide linkers: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved... Agent: Alkermes, Inc.
20130336926 - Il-1 family variants: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.... Agent: Amgen Inc.
20130336924 - Ligands modified by circular permutation as agonists and antagonists: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity,... Agent:
20130336927 - Culturing circular ssdna viruses for the production of vaccines: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure... Agent:
20130336928 - Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s): Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical... Agent:
20130336929 - Methods and cells for identifying rig-i pathway regulators: Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.... Agent: Kineta, Inc.
20130336930 - Myxoma virus mutants for cancer treatment: Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.... Agent: Robarts Research Institute
20130336939 - Antinematodal methods and compositions: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.... Agent: Technion Research And Developement Foundation Ltd.
20130336940 - Modified pig islets for diabetes treatment: The present invention relates to a modified pig islet capable of producing higher levels of glucagon than a native pig islet or capable of producing a glucagon analog, and methods for obtaining thereof. The invention also relates to a method for treating Diabetes Mellitus, and/or for regulating blood glucose levels... Agent: Universite Catholique De Louvain
20130336938 - Transplantation of cells into the nasal cavity and the subarachnoid cranial space: A method of transplanting cells into a subject is disclosed. The method comprises transplanting the cells into the paranasal sinus of the subject or the subarachnoid cavity situated between the frontal bone of skull and the olfactory bulb of the subject. Devices for paranasal sinus transplantation and subarachnoid cavity transplantation... Agent:
20130336931 - Synbiotic compositions for restoration and reconstitution of gut microbiota: The present invention relates to synbiotic compositions comprising probiotic bacterial strains and prebiotic substances that, when combined exhibit synergistic behavior. The synergetic compositions will stimulate the indigenous microflora to restore and reconstitute in vivo gut like conditions after antibiotic associated diarrhea (AAD), and/or other gut infections caused by gastrointestinal pathogens,... Agent: Lavivo Ab
20130336941 - Long lasting absorption of flavonoids: The present invention relates to methods for a ong-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and α-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-gluoside.... Agent:
20130336944 - Lactococcus lactis strains for use in improving digestive condition: The present invention concerns strains of Lactococcus lactis capable of inhibiting the growth of a pathogenic microorganism and/or improving the intestinal epithelial barrier integrity. These strains are suitable for use in the treatment or prevention of a digestive disorder.... Agent: Compagnie Gervais Danone
20130336943 - Means and methods for activating vagus nerve: An object of the present invention is to provide an effective means and method for activating vagal afferent nerve. The present invention provides a vagus nerve activator comprising bacterial cells and/or a treated product of a lactic acid bacteria as active ingredient(s).... Agent: Calpis Co., Ltd.
20130336942 - Use of a probiotic to regulate body weight: The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of... Agent:
20130336932 - Novel salmonella bacteriophage and uses thereof: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).... Agent: Intralytix, Inc.
20130336933 - 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes: The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of... Agent: Cellartis Ab
20130336936 - Cell transplantation: The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital
20130336937 - Chondrogenic differentiation media and methods for inducing chondrogenic differentiation of cells: The invention provides chondrogenic differentiation media comprising chondrogenic growth factors and low-molecular-weight sulfated polysaccharide derivatives of marine native exopolysaccharides (EPS) excreted by mesophilic marine bacteria from deep-sea hydrothermal environments. The invention relates to methods for inducing chondrogenic differentiation in pluripotent or multipotent cells, to cartilage tissues obtained by such methods,... Agent: Institut Francais De Recherche Pour L'exploitation De La Mer
20130336935 - Compositions and methods for restoring or rejuvenating stem/progenitor cell function: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or... Agent:
20130336934 - Multipotent stem cells and uses thereof: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which... Agent: The Brigham And Women's Hospital, Inc.
20130336945 - Stable compositions of tetrahydrobiopterin: The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.... Agent: Rubicon Research Private Limited
20130336946 - Fusion proteins and methods for treating hiv infection and aids related symptoms: The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection.... Agent: Tianjin Xiji Biotechnology Co., Ltd.
20130336948 - Cosmetic: A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein... Agent: Restorsea, LLC
20130336947 - Peptides and uses: Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in... Agent: FundaciÓ Privada Centre De RegulaciÓ GenÓ Mica
20130336951 - Compositions and methods for modulating ampa receptor-mediated excitotoxicity: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are... Agent: Centre For Addiction And Mental Health
20130336950 - Material combination for treating inflammatory or infectious diseases: A material combination is configured to treat or prevent inflammatory and infectious diseases caused by fastidious anaerobic or facultative anaerobic microorganisms, such as bacteria or Candida sp. The material combination includes at least one antimicrobial peptide that can be activated by a reducing substance, and at least one reducing agent.... Agent:
20130336949 - Tetrazole compounds for reducing uric acid: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that... Agent: Wellstat Therapeutics Corporation
20130336952 - Pharmaceutical compositions and related methods: The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that... Agent: Healor Ltd.
20130336953 - Use of creatine kinase for preventing or treating addiction to opiates: The present invention relates to creatine kinase for use as a medicinal product or in the prevention or treatment of addictions or of addictive disorders associated with opiates, and to various other analytical uses or for filtration of creatine kinase.... Agent: Centre National De La Recherche Scientifique - Cnrs
20130336955 - Antimicrobial fusion compounds and uses thereof: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.... Agent: Valiant Biopharma Sdn Bhd
20130336954 - Staphylococcal phage2638a endolysin amidase domain is lytic for staphylococcus aureus: Staphylococcus aureus is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic for S. aureus when exposed externally, making it a new antimicrobial candidate. It shares a common protein organization with over 40 other staphylococcal... Agent:
20130336956 - Recombinant elastase proteins and methods of manufacturing and use thereof: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described... Agent: Proteon Therapeutics, Inc.
20130336958 - Notch inhibition in the treatment of cardiovascular disease: The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and... Agent: The Brigham And Women's Hospital, Inc.
20130336957 - Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography: Disclosed herein are compositions and methods for the isolation and purification of antibodies from a sample matrix. In particular, the present invention relates to compositions and methods for isolating and purifying antibodies exhibiting low or high binding capacity for Protein A resin. In certain embodiments, the methods herein employ a... Agent: Abbvie, Inc.
20130336967 - Anti-bst2 antibody: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The... Agent: Sbi Biotech Co., Ltd.
20130336964 - Anti-trka antibodies, derivatives and uses thereof: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the TrkA amino acid sequence, medical uses thereof and a pharmaceutical composition comprising at least one of the above antibody, recombinant or synthetic antigen-binding fragments thereof.... Agent: Rottapharm Biotech S.r.l.
20130336963 - Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which... Agent: Chugai Seiyaku Kabushiki Kaisha
20130336962 - Aziridine bisphenol ethers and related compounds and methods for their use: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional... Agent: British Columbia Cancer Agency Branch
20130336961 - B cell depletion for central nervous system injuries and methods and uses thereof: Therapeutic B lymphocyte (B cell) depleting antibodies and methods and uses thereof in the treatment of patients having central nervous system injuries are described.... Agent: The Ohio State University
20130336966 - Coronin 1 modulators for the treatment of autoimmune and lymphoproliferative disorders and mycobacterial infections: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a... Agent: University Of Basel
20130336959 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20130336960 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20130336965 - Novel ring-substituted n-pyridinyl amides as kinase inhibitors: e
20130336968 - Pharmaceutical formulation comprising a biopharmaceutical drug: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.... Agent: Hexal Ag
20130336969 - Use of olfactomedin-4 protein (olfm4) in colorectal cancer diagnosis: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the... Agent: Institut De Cancerologie De L'ouest
20130336970 - Compositions and methods for treating and diagnosing cancer: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin... Agent:
20130336973 - Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain: Provided herein are isolated heteromultimers comprising: at least one single domain antigen-binding construct attached to at least one monomer of a heterodimer Fc region; wherein the heterodimer Fc region comprises a variant CH3 domain comprising amino acid mutations that promote the formation of said heterodimer with stability comparable to that... Agent:
20130336971 - Homodimeric protein constructs: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific... Agent: Vaccibody As
20130336974 - Method for delivering agents into cells using bacterial toxins: The invention provides compositions and methods for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic cell. The bioactive moiety is linked to an A component of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate... Agent: President And Fellows Of Harvard College
20130336972 - Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc: The present invention relates to DCC-fusion proteins, nucleic acid molecules encoding the DCC-fusion proteins, as well as methods for their production and their use in treatment of cancer such as colorectal cancer, NSCLC and metastatic breast cancer. The present invention also relates to methods of treating cancer such as colorectal... Agent:
20130336975 - Anti-ngf compositions and use thereof: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also... Agent:
20130336978 - Binding members for interleukin-4 receptor alpha (il-4ra) - 173: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD.... Agent:
20130336979 - Diagnostic and treatment of chronic heart failure: The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure.... Agent:
20130336976 - Human immune therapies using a cd27 agonist alone or in combination with other immune modulators: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist,... Agent:
20130336977 - Single-chain multivalent binding proteins with effector function: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as... Agent: Emergent Product Development Seattle, LLC
20130336981 - Methods and means for the production of ig-like molecules: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.... Agent: Merus B.v.
20130336980 - St2l antagonists and methods of use: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.... Agent: Janssen Biotech, Inc.
20130336982 - Antagonist antibodies against gdf-8 and uses therefor: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose... Agent:
20130336984 - Antagonistic dr3 ligands: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.... Agent: Novo Nordisk A/s
20130336983 - Prognosis and treatment of breast cancer: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis... Agent: Trustees Of Dartmouth College
20130336985 - Medicament and a method for regulation of the vascular tone: The method of treatment for diseases accompanied by disturbances of the vascular tone utilizes the use of ultra low doses of antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated form produced by... Agent:
20130336987 - Identification of therapeutic targets in cutaneous scc: The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers.... Agent: University Of Dundee
20130336986 - Kinases as targets for anti-diabetic therapy: The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, and GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism.... Agent: Max-planck-gesellschaft Zur FÖ Rderung Der Wissenschaften E.v.
20130336988 - Methods for treating early stage or mild neurological disorders: This disclosure relates to modulation of the interactions between proNTs and p75NTR/SorCS2 expressed on neuronal cells. Inhibition of such interactions is useful for reducing unwanted synaptic elimination, neurite pruning and/or other neuronal structural collapses, and for treating early stage and mild neurological disorders including mild cognitive impairment.... Agent: Cornell University
20130336989 - Methods of identifying a patient population: Provided herein is a method for identifying a patient as a candidate for treatment with an aggrecanase inhibitor. Also provided is a method of evaluating the effectiveness of an aggrecanase inhibitor.... Agent: Glaxo Group Limited
20130336992 - Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.... Agent: Amgen Inc.
20130336990 - Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of... Agent: North West University
20130336991 - Sp35 antibodies and uses thereof: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of... Agent: Biogen Idec Ma Inc.
20130336993 - Modulation of the immune response: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.... Agent: The Brigham And Women's Hospital, Inc.
20130336994 - Extracellular targeted drug conjugates: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the... Agent: Centrose, LLC
20130336995 - Photosensitizing antibody-fluorophore conjugates: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
20130336996 - Novel compositions of tlr7 and/or tlr8 agonists conjugated to lipids: A conjugated compound of formula Q-Z—R4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the... Agent: Cayla
20130336997 - Phosphorylated dendrimers as antiinflammatory drugs: Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.... Agent: Centre National De La Recherche Scientifique
20130336999 - Peptide with reduced dimer formation: The present invention relates to peptide which are formulated or engineered to prevent or reduce the formation of dimers.... Agent: Circassia Limited
20130336998 - Vaccination in newborns and infants: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more... Agent: Curevac Gmbh
20130337000 - Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.... Agent: Genocea Biosciences, Inc.
20130337001 - Immunogenic composition for treatment of hepatitis c, a method for preparing the composition and use thereof for treating hepatitis c: This disclosure provides an immunogenic composition comprising an amount of isolated dendritic cells comprising at least one fragment of a hepatitis C protein selected from the group consisting of the core protein of hepatitis C and the NS3 protein of hepatitis C, the fragment does not suppress activity of dendritic... Agent:
20130337002 - Peptide scaffold design: i
20130337003 - Engineered type iv pilin of clostridium difficile: The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.... Agent: University Of Maryland, Baltimore
20130337004 - Polysaccharide-protein conjugate vaccines: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The Department Of
20130337005 - Nanoparticles for providing immune responses against infectious agents: Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate... Agent: Midatech Limited
20130337006 - Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines: The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.... Agent:
20130337007 - Salmonid alphavirus protein e2: The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.... Agent:
20130337008 - Adenoviral vector-based dengue fever vaccine: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first... Agent: Genvec, Inc.
20130337009 - Chimeric dna vaccine compositions and methods of use: The present invention relates to compositions and methods for the prevention and treatment of infectious diseases. In particular, the invention relates to stimulating an immune response in a subject to prevent or treat diseases by administering a DNA vaccine encoding regulatory elements derived from the caprine arthritis encephalitis goat lentivirus... Agent: Immunogenetix Therapeutics, Inc.
20130337010 - Reassortant btv and ahsv vaccines: The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV.... Agent: Merial Limited
20130337011 - Recombinant mycobcterium as a vaccine: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.... Agent: Vakzine Projekt Management Gmbh
20130337012 - Tissue targeted antigenic activation of the immune response to treat cancers: The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed... Agent: Qu Biologics Inc.
20130337013 - Recombinant bacterium comprising a toxin/antitoxin system: The present invention encompasses recombinant bacteria suitable for live attenuated vaccines, and methods of use thereof. One aspect of the present invention encompasses a recombinant Salmonella bacterium. The bacterium comprises a first promoter operably linked to a nucleic acid encoding a toxin and a second promoter operably linked to a... Agent: The Arizona Board Of Regents For And On Behalf Of Arizona State University
20130337014 - Compositions and methods for controlling diseases in animals: Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and... Agent: Zoetis Products LLC
20130337018 - Antibody therapy for use in the digestive tract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described... Agent: Avaxia Biologics, Incorporated
20130337015 - C-met modulator pharmaceutical compositions: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.... Agent:
20130337019 - Compositions containing quaternary ammonium compounds: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at... Agent: Novagali Pharma Sa
20130337017 - Fusion proteins of collagen-binding domain and parathyroid hormone: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with... Agent: Ochsner Clinic Foundation
20130337016 - Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene: The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence... Agent: Cadila Healthcare Limited
20130337021 - Percutaneous absorption preparation comprising anti-dementia drug: The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a... Agent:
20130337020 - Pharmaceutical compositions: Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in... Agent: Alpharma Pharmaceuticals LLC
20130337022 - Pharmaceutical dosage form: A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers... Agent: University Of The Witwatersrand, Johannesburg
20130337024 - Carotenoid-containing composition and method for producing the same: Provided are a carotenoid-containing composition containing at least one carotenoid; at least one selected from the group consisting of ascorbic acid, derivatives thereof and salts of the acid and the derivatives; and an emulsifier, the at least one selected from the group consisting of ascorbic acid, derivatives thereof and salts... Agent: Fujifilm Corporation
20130337026 - Cosmetic composition comprising silica aerogel particles and silicone oils: The present invention relates to a composition comprising a mixture:—of hydrophobic silica aerogel particles having a specific surface area per unit of mass (SM) ranging from 500 to 1500 m2/g and a size expressed as the volume-average diameter (D[0.5]) ranging from 1 to 1500 μm, and—of at least one first... Agent: L'oreal
20130337025 - Fine powder of biosourced aliphatic polyester and production method thereof: The invention relates to a method for the production of biosourced aliphatic polyester powder having a volume median diameter of less than 30 μm, comprising: a step consisting in supplying an aliphatic polyester having an inherent viscosity of less than 0.5 dl/g; and a step consisting in grinding the polyester,... Agent: Arkema France
20130337023 - Polyurea capsules prepared with aliphatic isocyanates and amines: Polyurea capsules that encapsulate active materials in polymeric walls resulting from the polymerization of an aliphatic polyisocyanate and a cross-linking agent such as a diamine, amphoteric amine or guanidine amine/salt are provided as are consumer products containing said polyurea capsules and for methods for producing such capsules.... Agent: International Flavors & Fragrances Inc.
20130337027 - Medical devices and implements with liquid-impregnated surfaces: Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween.... Agent: Massachusetts Institute Of Technology
20130337028 - Biomimetic peptides for bone augmentation: The present invention relates to synthetic peptides for use in bone tissue repair and regeneration applications. The present invention also relates to various compositions and devices (including implantable orthopedic/dental devices) that contain the synthetic peptides of the present invention, and methods involving the use of the synthetic peptides of the... Agent: Nanovis, Inc.
20130337029 - Cured oil-hydrogel biomaterial compositions for controlled drug delivery: The present invention is generally directed to materials, gels, coatings and films prepared using a biomaterial (e.g., a fatty acid-based material comprising a network of cross-linked fatty acids) and a fixating material, layer or film (e.g., a fixating material comprising Na—CMC). The materials, gels, coatings and films disclosed herein can... Agent:
20130337030 - Neutrally buoyant ingestible compositions: A nutriment or medicament may have a neutral buoyancy for being suspended in a liquid, or at a desired depth within the liquid to improve consumption of the nutriment or medicament and reduce waste. Disclosed also are methods for making and using the neutrally buoyant products.... Agent: Empire Technology Development LLC
20130337034 - Biofunctionalized magnetic nanowires: Magnetic nanowires can be used as an alternative method overcoming the limitations of current cancer treatments that lack specificity and are highly cytotoxic. Nanowires are developed so that they selectively attach to cancer cells via antibodies, potentially destroying them when a magnetic field induces their vibration. This will transmit a... Agent: King Abdullah University Of Science And Technology
20130337036 - Method of using fibrous tissue sealant: Disclosed herein is a fibrous tissue sealant in the form of an anhydrous fibrous sheet comprising a first component which is a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking the first component when the sheet is exposed to an aqueous medium, thereby forming... Agent: Actamax Surgical Materials, LLC
20130337033 - Nitric oxide-releasing compositions and methods: The invention relates to nitric oxide-releasing compositions comprising polyacrylonitrile polymers that are diazeniumdiolated, and to medical devices comprising such compositions, as well as to methods of making and using the compositions and medical devices.... Agent:
20130337035 - Placental tissue grafts: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer... Agent: Mimedx Group, Inc.
20130337031 - Topical formulations, systems and methods: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of... Agent: Nuvo Research Inc.
20130337032 - Topical patch for pain relief using cooling agent: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble... Agent: Teikoku Pharma Usa, Inc.
20130337037 - Hemostatic compositions and therapeutic regimens: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency... Agent: Marine Polymer Technologies, Inc.
20130337038 - Chimeric fibronectin matrix mimetics and uses thereof: The present invention is directed to recombinant fibronectin peptide mimetics and wound healing compositions containing the same. Other aspects of the present invention include wound healing dressings that comprise the wound healing composition of the present invention and a wound dressing material and methods of treating wounds using these compositions.... Agent: University Of Rochester
20130337051 - Advanced active liposomal loading of poorly water-soluble substances: The present invention relates to the field of encapsulation of substances with low aqueous solubility in liposomes, especially via active loading. The present inventors have surprisingly found that efficient active loading of liposomes with high liposome loading can be achieved by first solubilizing a functional compound, which is itself hardly... Agent: To-bbb Holding B.v.
20130337041 - Charged phospholipid compositions and methods for their use: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of... Agent: Cerenis Therapeutics, S.a.
20130337040 - Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the... Agent:
20130337043 - Composition used for thermotherapy and producing method thereof and method to treat cancer: A composition used for thermotherapy includes a carrier structure and a plurality of metal particles. The carrier structure includes a lipid layer, a positive charged polymer and a surface active polymer. The positive charged polymer and the surface active polymer are dispersed on the lipid layer by non-covalent bonding. The... Agent:
20130337047 - Compositions for treating oral and periodontal infections: The present invention provides novel compositions, and their methods of manufacture and use, comprising a formulation with a mucoadhesive polymer carrying a positive charge such as low molecular weight chitosan, a negatively charged lipid and H2 antagonist useful in the prevention and treatment of oral infectious disease in a nanotechnology... Agent: Zarzatech, Inc.
20130337045 - Controlled activation of complement components for use as endogenous adjuvant: The invention relates to a pharmaceutical composition made of one or more preparation and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and at least one antigen für vaccination.... Agent:
20130337039 - Internalizing erbb2 antibodies: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.... Agent: The Regents Of The University Of California
20130337048 - Method and compositions for treating hiv infection: A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-IκBα agent, an anti-IκBε agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating... Agent:
20130337046 - Methods for improved delivery of aminothiols, dimers of aminothiols, and heterodimers composed of aminothiols: The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly.... Agent:
20130337044 - Modulation of effector t cell responses by local depletion of complement component c3: The invention relates to a pharmaceutical composition for the modulation of effector T cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and of at least one antigen or allergen.... Agent:
20130337049 - Novel use of spiegelmers: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.... Agent: Noxxon Pharma Ag
20130337042 - Use of pvp-iodine liposomes for treatment of herpes: The invention concerns a method for the production of a pharmaceutical preparation for the treatment of Herpes forms that is characterized in, that the preparation comprises at least one antiseptic compound associated with a particular carrier.... Agent: Euro-celtique, S.a.
20130337056 - Coated solid pharmaceutical preparation: The invention is directed to coated solid pharmaceutical preparations having a very thin coating in the nanometer range and a method for producing such preparations. The coated solid pharmaceutical preparation can be prepared by using atomic layer deposition (ALD).... Agent: Merck Patent Gmbh
20130337055 - Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that... Agent:
20130337053 - Novel formulations and methods: A formulation comprising T3/VIP nanoparticles, wherein the T3/VIP nanoparticle comprises both T3 and VIP encapsulated or immobilized on a bioabsorbable polymer. The invention further provides for methods of making a formulation comprising a T3/VIP nanoparticle. The invention further provides for methods of treatment utilizing said T3/VIP nanoparticle.... Agent:
20130337057 - Novel herbal composition for the treatment of kidney stone and other urinary tract disorders: Discloses a novel synergistic herbal composition comprising combination of therapeutically effective amount of Vrun bhavit, Kadalikshar, Apamargkshar, Yavkshar and optionally Gomutrakshar along with pharmaceutical acceptable additives, useful for the treatment of kidney stone and other urinary disorders like inflammation and urinary stent related problems.... Agent:
20130337052 - System and method of reducing impairment of alertness, concentration, motivation, and creativity caused by medication: Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium... Agent:
20130337054 - Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibrinolytic or hemostatic agent: A method and drug delivery device for reducing menstrual blood loss in a female are provided. The method comprises administering intravaginally to the female a therapeutically effective amount of an active agent on a delivery device directly to uterine cavity during a menstrual period, wherein the active agent is any... Agent: Arstat Inc.
20130337058 - Micronized tanaproget and compositions containing same: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and... Agent: Wyeth LLC
20130337059 - Oral pharmaceutical dosage forms: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.... Agent: Durect Corporation
20130337060 - Oral pharmaceutical dosage forms: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.... Agent: Durect Corporation
20130337061 - Pharmaceutical compositions for sleep apnea: Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma... Agent: Collegium Pharmaceutical, Inc.
20130337062 - Gastro-resistant enzyme pharmaceutical compositions: The present invention generally relates to compacted pharmaceutical compositions (such as tablets) comprising one or more enzymes, where the composition is monolithic or multiparticulates (such as mini-tablets, micro-tablets, or prills), or where the composition has multiple layers with the outermost layer containing one or more enzymes.... Agent: Aptalis Pharma Canada Inc.
20130337063 - Pharmaceutical compositions of maraviroc and process for the preparation thereof: The present disclosure relates to solid dosage forms comprising the CCR5 co-receptor antagonist maraviroc. More particularly, the present disclosure relates to a solid oral dosage form containing maraviroc which has favorable disintegration properties.... Agent: Hetero Research Foundation
20130337064 - Pharmaceutical composition: e
20130337065 - Aptamer bioconjugate drug delivery device: A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a... Agent: Ecosynthetix Ltd.
20130337068 - Carotenoid particles and uses thereof: This invention relates to the incorporation of bioactive cargo molecules into particles with carotenoids, such as lycopene. The incorporation of a cargo molecule into a carotenoid particle may for example increase the bioavailability of the cargo molecule in the bloodstream compared to other delivery systems. Carotenoid particles as described herein... Agent: Ip Science Limited
20130337066 - Membrane encapsulated nanoparticles and method of use: Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the... Agent: The Regents Of The University Of California
20130337067 - Non-viral nanoparticle-based delivery system: The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at... Agent:
20130337069 - Silicon nanoparticlefor photodynamic cancer treatment utilizing quantum dot optical properties: Quantum active sized silicon nanoparticles with a silicon core covered by a thin 0.5-1.5 nm oxide/nitride shell are described for light exposure in the 300-600 nm range for transforming atmospheric oxygen to singlet oxygen for causing cell apoptosis as a type of photodynamic cancer therapy. A method of use of... Agent:
20130337070 - Coated nanoparticle therapy for skin cancer: Disclosed herein are compositions useful as therapy and prevention of skin neoplasms, namely melanoma. Also disclosed herein are methods of using polymer-coated cerium nanoparticles as therapy against skin cancer. Further, disclosed are combination therapies involving polymer-coated cerium nanoparticles with other anti-neoplastic agents.... Agent: University Of Central Florida Research Foundation Inc.
20130337073 - Controlled release particles: A controlled release particle includes a core formed by suspension polymerization of a core ingredient component containing an antibiotic compound and a first polymerizable vinyl monomer, and containing a first polymer of the first polymerizable vinyl monomer and the antibiotic compound present in the first polymer; and a shell formed... Agent: Japan Enviro Chemicals Ltd.
20130337072 - Controlled release particles and production method thereof: A controlled release particle includes a core containing an antibiotic compound, and a shell covering the core. The controlled release particle is obtained by a production method including a first step in which a first component containing an antibiotic compound and a polymerizable vinyl monomer is subjected to suspension polymerization... Agent: Japan Envirochemicals, Ltd.
20130337071 - Radiofrequency-induced synchronization of in situ hyperthermia and chemotherapy via magnetic-nanoconjugates: The present invention relates to a magnetic nanoparticle for tumor therapy, comprising: a magnetic core; a shell encapsulating a surface of the magnetic core, wherein the shell is made of a polymer with carboxylic groups; a poly-nucleotide chain connected to a surface of the shell; an anti-tumor drug connected to... Agent:
20130337075 - Nanomedicines for early nerve repair: The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions... Agent: Purdue Research Foundation
20130337076 - Particles containing a growth factor, and uses thereof: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.... Agent: Universite De Rouen
20130337074 - Use of cytokine-releasing, biodegradable particles in hyaluronic acid for the treatment of cartilage defects, in particular of osteoarthrosis: The present invention relates to a composition comprising, or consisting of 2-50 mg/ml hyaluronic acid, 0.1-500 mg/ml of biodegradable particles with an average mean particle diameter of 1 nm-500 μm, 1 pg/ml-10 μg/ml cytokines, where the concentrations specified are based in each case on the total volume (w/v) of the... Agent:
20130337077 - Nanospheres for therapeutic agent delivery: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from... Agent:
20130337078 - Particulate constructs for release of active agents: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.... Agent: Celator Pharmaceuticals, Inc.
20130337079 - Method for producing oyster meat essence containing large amount of antioxidants having high antioxidative power and high orac value: An oyster meat is stored in an extraction container where water is accumulated. An oyster meat essence is extracted to generate an extract liquid. The extract liquid is injected to a centrifuge, and concurrently the centrifuge is rotated at a centrifugal acceleration where an antioxidant substance with high antioxidative potency... Agent:
20130337080 - Dietary supplements for promotion of growth, repair and maintenance of bone and joints: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.... Agent: Esm Technologies, LLC
20130337081 - Mixing device, mixture fluid production device, mixture fluid production method, and mixture fluid, oxygen-containing water and ice produced by the same: A mixing device includes a mixing section that mixes a liquid-phase fluid with one kind or two or more kinds among a solid, a gas, and a liquid-phase fluid different from the above-mentioned liquid-phase fluid, in which the mixing section includes a supply hole for a fluid, a discharge hole... Agent:
20130337082 - Noggin inhibitory compositions for ossification and methods related thereto: This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement... Agent: Emory University
20130337083 - Nanoceria for the treatment of oxidative stress: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These... Agent: Cerion Enterprises, LLC
20130337084 - Nanoceria with citric acid additive: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid, an oxidant, and water, is adjusted to a predetermined range of pH, held at temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. Dispersions of... Agent: Cerion Enterprises, LLC
20130337085 - Use of ide as a biomarker for a scalp condition: The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff... Agent: L'oreal
20130337086 - Mineral salt-sulfonic acid compositions and methods of use: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.... Agent: Bmg Pharma LLC
20130337089 - Composition for preventing or treating hearing loss: Disclosed is a pharmaceutical composition for preventing or treating hearing loss, comprising Cuscuta japonica Choisy extract, or the extract of Rehmannia glutinosa Libschitz var. purpurea MAKINO and Cuscuta japonica Choisy. In addition, the present invention provides a food composition for preventing or ameliorating hearing loss, comprising Cuscuta japonica Choisy extract,... Agent: University-industry Cooperation Group Of Kyung Hee University
20130337087 - Methods and models for assessing anti-aging benefits of agents: A screening method for identifying an agent as effective for providing an anti-aging skin benefit is provided. The screening method includes culturing first and second human skin samples from about 3 days to about 19 days, wherein the first and second human skin samples are derived from a human skin... Agent:
20130337088 - Methods for treating scars and aging skin: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically... Agent:
20130337090 - Plant extracts for treating burns and chronic wounds: The present invention provides compositions and methods for treating burns and chronic wounds, particularly compositions comprising an oil extract or oily suspension of a combination of plant material derived from several plant species for treating burns and chronic sores.... Agent: Skin Matrix Ltd.
20130337091 - Pharmaceutical use: The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and α-lipoic acid and/or extract of green... Agent: Lucolas-m.d. Ltd.
20130337092 - Phytonutrient compositions and methods of use: Phytonutrient based compositions and methods of using the same for preventing, reducing, or treating genetic damage induced by environmental toxins are disclosed. Additionally, said compositions and methods are used to reduce oxidized low density lipoproteins (OxLDL), myeloperoxidase (MPO), and plasminogen activator inhibitor-1 (PAI-1).... Agent: Metaproteomics, LLC
20130337093 - Composition comprising natural extracts: The invention relates to a method for providing an awaking effect and specifically affecting post lunch dip in a subject comprising providing a subject with a composition comprising an isolate of guarana plant, and at least one of (i) isolate of ginkgo biloba plant or functional analogue thereof and (ii)... Agent:
20130337094 - Nutritional supplement comprising nut and seed oil composition: The present invention provides a novel composition of nut and seed oils, specifically; walnut oil, almond oil, avocado oil, pistachio oil and flaxseed oil for use in maintaining and improving health in a convenient and cost-effective manner; for obtaining essential fatty acids that are required for normal body functioning; for... Agent: Dr. Baker Says, Inc.
20130337095 - Antimicrobial composition and its method of use: An antimicrobial composition is provided, including melaleuca oil, or an isolated fraction or an active agent or equivalent thereof, manuka oil, or an isolated fraction or an active agent or equivalent thereof, and at least one galloyl moiety.... Agent: Waikatolink Limited
20130337096 - Chewable vehicle for mouth absorption: The present document describes a buccal delivery dosage form for administration of an active ingredient, including pharmaceutically, pharmacologically, or biologically active ingredients, in the mouth of a subject. The buccal delivery dosage form by-passes the gastrointestinal tract metabolism. The buccal delivery dosage form may comprise chemical permeation enhancers, excipients, texture... Agent: Technologies Khloros Inc.12/12/2013 > 159 patent applications in 87 patent subcategories. patent applications/inventions, industry category
20130330274 - Compositions and methods for detecting and treating cancer: Macrophages within the tumor microenvironment, also called tumor associated macrophages (TAMs) have been shown to play a major role in the growth and spread of many types of cancer. Cancer cells produce cytokines that cause the macrophages to differentiate into an M2 subtype. We have designed a mannosylated liposome (MAN-LIPs)... Agent: University Of Virginia Patent Foundation D/b/a University Of Virginia Licensing & Ventures Group
20130330275 - Misfolded proteins in cancer treatment and diagnosis: Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein,... Agent:
20130330276 - Conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes: A conjugate of human albumin (HA) and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) insoluble in aqueous medium at a pH of 3-8.5 and whose IR spectrum shows an absorption at about 700 cm−1 is described; a complex is further described consisting of a conjugate of HA and p-SCN-Bn-DOTA (HAC) according to claim 1... Agent: UniversitÀ Degli Studi Di Genova
20130330277 - Methods of using sustained release aminopyridine compositions: Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.... Agent: Acorda Therapeutics, Inc.
20130330279 - Nanoparticle mediated gene therapy, diagnostic products and therapeutic products for breast cancer: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target... Agent: Nnanoaxis, LLC
20130330280 - Aqueous method of making magnetic iron oxide nanoparticles: The invention discloses an aqueous method of making polymer coated superparamagnetic nanoparticles. Nanoparticles made by the method are included in the invention.... Agent: University Of Central Florida Research Foundation, Inc.
20130330278 - Multicolored ph-activatable fluorescence nanoplatform: The present invention relates to pH-tunable, highly activatable multicolored fluorescent nanoplatforms and methods of using the nanoplatforms in a variety of applications including, but not limited to, investigating fundamental cell physiological processes such as pH regulation in endocytic vesicles, endosome/lysosome maturation, and effect of pH on receptor cycling and trafficking... Agent:
20130330281 - Pharmaceutical compositions: A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.... Agent: Cipla Limited
20130330282 - Spray formulations with reduced clogging/sedimentation characteristics: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica... Agent:
20130330283 - Oral care compositions: Flavour components for use in oral care compositions containing a metal salt, compositions comprising the flavour components, and methods of making and using the same. The flavour components comprise a taste -masking agent comprising cinnamic aldehyde, eugenol and eucalyptol and one or more flavouring agents selected from L-menthol, N-ethyl-p-menthane-3-carboxamide, anethole,... Agent: Colgate-palmolive Company
20130330285 - Heated spray system for applying tanning solution: An improved method and apparatus for applying tanning solutions to a human body. Preferred embodiments of the present invention provide a spray gun that heats the air used to propel the tanning solution, rather than the tanning solution itself, in order to make the application of the tanning solution much... Agent:
20130330284 - Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.... Agent: Varinel Inc
20130330287 - Cosmetic composition comprising a cucurbic acid compound and a hydrophobic inulin: The invention relates to a cosmetic composition in oil-in-water emulsion form comprising a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, R3 denoting H or a C1-C4 alkyl radical, optionally substituted with one or more hydroxyl groups; R2 represents a hydrocarbon-based radical containing from 1... Agent: L'oreal
20130330286 - Inhibitor of endothelin action and skin-whitening agent: e
20130330288 - Liquid cosmetic: To provide a liquid cosmetic which is loaded into a liquid applicator having an applying part and suitably used as a cosmetic for eye-makeup around the eyes, the liquid cosmetic comprises, at least, 1 to 20% by mass of high-brightness particles, 2 to 10% by mass of film-forming resin, 0.3%... Agent: Mitsubishi Pencil Company, Limited
20130330289 - Lip balm: A lip balm for protecting and rehydrating lips is disclosed containing a synthetic ceramide, an anti-irritant compound, sodium hyaluronate, a cosmetic wax, boswellian oil, extract of the Portuluca pilosa plant, a peptide, dehydrated microspheres of marine collagen and glycosaminoglycans, and mica.... Agent:
20130330290 - Perspiration and odor control compositions: The present disclosure is directed to a cosmetic composition for controlling perspiration and odor. Despite being free of volatile silicones—which have garnered a bad reputation due to their ecotoxicity and bioaccumulability in aquatic species—the composition of the instant disclosure replicates the textural and sensorial benefits provided by the use of... Agent: L'oreal Paris
20130330291 - Leave-in hair conditioning composition: Present invention relates to a non-aqueous leave-in conditioning composition for hair, especially for strongly damaged hair by chemical processes such as permanent shaping, oxidative colouration and bleaching. Accordingly, conditioning compositions of present invention comprise one or more cyclomethicone at a concentration of at least 50% by weight calculated to total... Agent:
20130330292 - Polyurea capsules prepared with a polyisocyanate and cross-linking agent: Polyurea capsules that encapsulate active materials in polymeric walls resulting from the polymerization of an aromatic or aliphatic polyisocyanate and a cross-linking agent are provided as are consumer products containing said polyurea capsules and for methods for producing such capsules.... Agent: International Flavors & Fragrances Inc.
20130330293 - Bio-nano power cells and their uses: The present invention concerns bio-nano power cells and methods of their manufacture and use. More particularly, the present invention relates to the preparation of bio-nano power cells that are biocompatible and capable of producing flash, intermittent, or continuous power by electrolyzing compounds in biological systems.... Agent: Bio-nano Power
20130330295 - Antigenic gly1 polypeptide: The disclosure relates to antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against human bacterial pathogens.... Agent:
20130330296 - Methods and compositions comprising il-7 receptor ligands: Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.... Agent: University Of Central Florida Research Foundation, Inc.
20130330294 - Serum amyloid a (saa) overrides regulatory t cells (treg) anergy: Methods and compositions are provided for inducing the proliferation of regulatory T cells. These methods find a number of uses, including, for example, treating autoimmune and rheumatoid diseases. Also provided are reagents and kits that find use in these methods.... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20130330297 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described.... Agent: Universita Degli Studi Di Cagliari
20130330298 - Zeaxanthin-enriched poultry egg: An object of the present invention is to provide zeaxanthin-enriched poultry eggs containing zeaxanthin at high concentrations. The present invention specifically relates to zeaxanthin-enriched poultry eggs obtained by feeding poultry with a poultry feedstuff containing zeaxanthin-producing bacteria.... Agent: Jx Nippon Oil & Energy Corporation
20130330306 - Composition containing human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells: A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases.... Agent: Medipost Co., Ltd.
20130330305 - Cytokine derivatives: The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof.... Agent:
20130330304 - Hepatocyte-like cells and uses thereof: The present invention relates to hepatocyte-like cells. Also disclosed are methods of making the cells and using the cells.... Agent: Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences
20130330299 - Composition and method for preventing or treating gout or hyperuricemia: A composition composed of a Lactobacillus bacterium, Bifidobacterium longum, and xylooligosaccharide is provided for use in reducing uric acid levels in the blood and preventing or treating hyperuricemia or gout.... Agent:
20130330307 - Feed additive composition: A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen... Agent: Dupont Nutrition Biosciences Aps
20130330308 - Feed additive composition: A feed additive composition comprising a direct fed microbial (DFM) in combination with a phytase derivable from Citrobacter spp. and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for... Agent: Dupont Nutrition Biosciences Aps
20130330309 - Nutraceutical and pharmaceutical composition: According to a first aspect, a composition comprises selenium, vitamin C, and at least 90% by weight of native or undenatured whey protein. According to a second aspect, a composition consists of cystine, selenium and vitamin C. According to further aspects, cosmetic formulations, pharmaceutical compositions and neutraceutical powders and beverages... Agent:
20130330303 - Brain tissue regeneration method: A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell,... Agent: National Center For Geriatrics And Gerontology
20130330301 - Enhanced medical implant: A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Pluripotent stem cells, other cells, and biologic constituents of the dental pulp may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem... Agent:
20130330300 - High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon: Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34+ bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.... Agent: University Of Southern California
20130330302 - Retinal pigment epithelial stem cells: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention... Agent: Regenerative Research Foundation
20130330311 - Antigen-presenting platelets and methods of eliciting an immune response: Provided herein are methods of producing an antigen-presenting platelet. Also provided herein are methods of eliciting an immune response in a subject using the antigen-presenting platelets described herein. Also provided are methods of screening for an immune response elicited by an antigen-presenting platelet. Further provided are isolated populations of platelets... Agent: University Of Rochester
20130330310 - Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells: Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of... Agent: University Of Florida Research Foundation, Inc.
20130330312 - Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-trna synthetases: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.... Agent:
20130330313 - Methods of disinfecting packages in aseptic packaging using antimicrobial peracid compositions with selected catalase enzymes: The present invention relates to specially selected catalase enzymes and their use in reducing hydrogen peroxide in applications, and particularly in aseptic packaging applications.... Agent:
20130330314 - Metal abstraction peptide with superoxide dismutase activity: Compositions comprising peptides that are capable of binding a metal are disclosed. Such compositions can be used for binding metal in a variety of contexts and environments. In various embodiments, peptides are used for antioxidant activity, anti-inflammatory activity, anti-pain therapy, as chemical reagents, and/or as superoxide dismutase mimics.... Agent: University Of Kansas
20130330315 - Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating... Agent: The Uab Research Foundation
20130330317 - Methods for treating lysosomal acid lipase deficiency: The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating a lysosomal acid lipase deficiency (LALD) disease, including administering to an... Agent:
20130330316 - Mutants of l-asparaginase: The present invention relates to a novel mutant of L-asparaginase enzyme characterized in having high thermostability, pH stability and no glutaminase activity useful for therapeutics and the process of preparing the same. The present invention specifically relates to mutant's MTCC 5580, MTCC 5581 and MTCC 5582 characterized in having higher... Agent: Indian Institute Of Technology (itt), Delhi
20130330319 - Cell migration modulator: The present invention provides a cell migration regulator capable of promoting or inhibiting cell migration, a method for regulating cell migration, and a pharmaceutical composition comprising such a regulator, etc. The cell migration regulator of the present invention comprises a peptide, a derivative thereof, or a salt of the peptide... Agent: Nihon University
20130330318 - Method for treating filtration failure after trabeculectomy surgery: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone,... Agent: Thrombogenics Nv
20130330321 - Injection paradigm for administration of botulinum toxins: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin... Agent: Allergan, Inc.
20130330320 - Methods for treating adhesive capsulitis: The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising... Agent:
20130330322 - Methods of treating skin aging with toll-like receptor 7 agonists: A method of reducing the appearance of skin aging comprising the step of applying a topical composition to the skin of a human exhibiting one or more signs of skin aging selected from fine lines, wrinkles, decreased skin elasticity, decreased light reflection, uneven pigmentation (dyschromia), coarse texture, dryness, solar lentigos,... Agent: Metabeauty, Inc.
20130330323 - Rapid generation of anti-idiotypic antibodies: In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.... Agent:
20130330327 - Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines: The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use... Agent: Bayer Intellectual Property Gmbh
20130330334 - Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd): The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing... Agent: Fraunhofer-gesellschaft Zur Fö Rderung Der Angewandten Forschung E.v.
20130330330 - Anti-il-tif antibodies: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases,... Agent: Zymogenetics, Inc.
20130330324 - Antibodies for epidermal growth factor receptor 3 (her3): This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and... Agent: Novartis Ag
20130330329 - B7-h7 antibodies and method of use: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Mayo Foundation For Medical Education And Research
20130330328 - Combination therapy for b cell lymphomas: The present disclosure provides methods for treating B cell lymphomas using a combination of anti-CD19 and anti-CD20 antibodies. Such methods provide therapeutic advantages over single antibody therapies, including prolonged anti-tumor activity and/or reduced dosages.... Agent: Medimmune, LLC
20130330325 - Means and methods for the prediction of treatment response of a cancer patient: The present invention relates to the field of treatment efficacy prediction in patients with malignant diseases. More precisely, this invention relates to the prediction of the efficacy of a treatment in cancer patients, based on the precise quantification of several biological markers that are related to the innate and adaptive... Agent:
20130330331 - Method of treating degenerative disorders of the nervous system: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.... Agent: The Regents Of The University Of California
20130330326 - Methods of treating cancer: Described are methods and compositions for treating epithelial tumors with a folate-vinca conjugate in combination with at least one other chemotherapeutic agent in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum-sensitive ovarian tumors.... Agent: Endocyte, Inc.
20130330333 - Treatment of angiogenesis disorders: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.... Agent: The Rockefeller University
20130330332 - Treatment of pemphigus: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.... Agent: Genentech, Inc.
20130330335 - Bioinformatic processes for determination of peptide binding: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.... Agent: Iogenetics, LLC
20130330337 - Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.... Agent: Morehouse School Of Medicine
20130330338 - Ctla4 proteins and their uses: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.... Agent: Abbvie Biotherapeutics Inc.
20130330336 - Fibroblast growth factor 21 proteins: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.... Agent: Eli Lilly And Company
20130330339 - Levels of blys/april heterotrimers in serum and use in diagnostic methods: The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for... Agent: Zymogenetics, Inc.
20130330340 - Production of n- and o-sialylated tnfrii-fc fusion protein in yeast: Production of recombinant Tumor Necrosis Factor Receptor fused to the Fc region of an antibody (TNFRII-Fc fragment fusion protein) in a glycoengineered yeast strain that is capable of producing sialylated N-glycans and O-glycans is described. Compositions of TNFRII-Fc fragment fusion protein comprising dystroglycan type O-glycans and sialylated N- and O-glycans... Agent:
20130330341 - Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments: The invention relates to the treatment and the diagnosis of a group of patients bearing specific alleles of single nucleotide polymorphisms in the promoter region of the VEGFA gene. These patients are more responsive to Aflibercept and more likely to be efficiently treated by anti-VEGF therapy.... Agent: Sanofi
20130330342 - Antibody fragments inhibiting hiv nef protein: The invention relates to antibody fragments with simple heavy chain or sdAbs, characterised in that they consist of anti HIV Nef-protein fragments corresponding to all or a portion of the HHV domains of camelids, particularly llamas.... Agent:
20130330344 - Antibody molecules having specificity for human ox40: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.... Agent: Ucb Pharma S.a.
20130330343 - Composition and method for the diagnosis and treatment of iron-related disorders: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.... Agent: Abbvie Deutschland Gmbh & Co. Kg
20130330346 - Chemokine receptor binding polypeptides: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the... Agent:
20130330345 - Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor... Agent: Chugai Seiyaku Kabushiki Kaisha
20130330348 - Anti-ngf antibodies and their use: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from... Agent: Abbott Laboratories
20130330347 - Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.... Agent: Abbvie Deutschland Gmbh & Co. Kg
20130330349 - High affinity molecules capable of binding a type a plexin receptor and uses of same: A high affinity molecule is provided. The high affinity molecule comprises a binding domain which binds a type-A plexin receptor, wherein said binding domain inhibits proliferative signals through said type-A plexin receptor but does not interfere with binding of a neuropilin or semaphorin 6A to said type-A plexin receptor.... Agent: Rappaport Family Institute For Research In The Medical Sciences
20130330350 - Antibody scaffold for homogenous conjugation: Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising... Agent: Medimmune, LLC
20130330351 - Antibody and methods for selective inhibition of t-cell responses: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods... Agent:
20130330353 - Regimens for treatments using anti-igf antibodies: Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two... Agent: Medimmune, LLC
20130330352 - Treatment of myocardial infarction using tgf beta antagonists: Disclosed herein is a method of treating a patient suffering a myocardial infarction, particularly an acute myocardial infarction, or of reducing an adverse consequence of a myocardial infarction in a patient comprising administering an antagonist of TGF-β to the patient during the acute stage of the myocardial infarction.... Agent: Genzyme Corporation
20130330354 - Stabilized liquid egg material for extended shelf life: The present invention is directed to shelf-stable liquid egg material, methods for making the same, and method of using the same. The present invention is also directed to an animal feed supplement containing a stabilized IgY antibody titer in liquid eggs stored at room temperature for extended periods of time... Agent:
20130330355 - Anti-il-1beta antibodies and methods of use: The present invention provides anti-IL-1β monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.... Agent: Apexigen, Inc.
20130330356 - Methods of treating disorders using human antibodies that bind human tnfalpha: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in... Agent: Abbvie Biotechnology Ltd.
20130330357 - Methods of treating disorders using human antibodies that bind human tnfalpha: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in... Agent: Abbvie Biotechnology Ltd
20130330358 - Crystal structure and peptide inhibitors of hausp deubiquitinase: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues,... Agent: University Of Southern California
20130330360 - Antagonistic dr3 ligands: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.... Agent: Novo Nordisk A/s
20130330359 - Composition and method for the diagnosis and treatment of iron-related disorders: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.... Agent: Abbvie Deutschland Gmbh & Co. Kg
20130330361 - Composition comprising expression or activity regulators of akap12 for treating central nerve system diseases: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical... Agent: Snu R&db Foundation
20130330362 - Humanized anti-egfr antibody l4-h3 and coding gene thereof: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is... Agent: Hefei Tairui Biotechnology Co., Ltd
20130330363 - Method of vaccination: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said... Agent: PCi Biotech As
20130330365 - Neprilysin inhibitors: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes... Agent:
20130330366 - Neprilysin inhibitors: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes... Agent:
20130330364 - Therapeutic formulations: The present invention concerns therapeutic formulations containing active agents, such bioactive cell populations, and methods of making and using the same.... Agent: Tengion, Inc.
20130330367 - Compositions with enhanced immunogenicity and/or reduced reactogenicity: The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation... Agent: Vaxinnate Corporation
20130330368 - Eye drop composition for prevention and treatment of ophthalmic diseases containing fusion protein of fk506 binding protein: Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of penetrating into the ocular tissue as an active ingredient.... Agent: Industry Acadeic Cooperation Foundation, Hallym University
20130330371 - Compositions relating to a mutant clostridium difficile toxin and methods thereof: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the... Agent: Wyeth LLC
20130330370 - Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of... Agent:
20130330369 - Reduction of antibody response against botulinum neurotoxin and variants thereof: The present invention provides a method of tolerizing a subject to botulinum toxin and botulinum toxin variants.... Agent: Allergan, Inc.
20130330372 - Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers: Disclosed are extracts prepared from primitive plants and fungi that have anti-cancer properties. The extracts are prepared by pulverizing the biological matter in a diluent. The extract can be administered to an individual or animal to kill cancer cells, prevent growth of cancer cells and teat cancer. The extracts may... Agent: Southern Connecticut State University
20130330373 - Cream composition enhancing skin absorption of glucosamine: The resent invention relates to a cream composition of glucosamine, including at least 10 wt %-15 wt % of glucosamine HCL, a methylsulfonylmethane component, a chondroitin component, and a cream base, wherein the composition promotes penetration of glucosamine from skin of affected area by synergistic interaction between components, in order... Agent:
20130330374 - Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.... Agent: Actogenix N.v.
20130330375 - Therapeutic cancer vaccine: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the... Agent: Cadila Pharmaceuticals Limited
20130330378 - Anisotropic biological pacemakers and av bypasses: The present invention provides biological pacemakers or AV-node bypasses The biological pacemakers or AV-node bypasses of the invention are useful for the treatment of, inter alia, cardiac arrhythmias and AV-node conduction defects.... Agent: President And Fellows Of Harvard College
20130330377 - C-met modulator pharmaceutical compositions: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.... Agent: Exelixis Inc.
20130330379 - Drug delivery compositions: The present invention relates material that is useful in drug delivery compositions. The material comprises cellulose nanofibers and/or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof.... Agent: Upm-kymmene Corporation
20130330382 - Fluorocarbon-linked peptide formulation: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino... Agent:
20130330381 - Methods of delivering stable topical drug compositions: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.... Agent: Transdermal Biotechnology, Inc.
20130330384 - Molecularly imprinted polymers having affinity for natriuretic peptides: The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the MIP is a nanoparticle (a molecularly imprinted polymeric nanoparticle (MIPNP)). Other aspects of the invention include methods of preparing an MIP having affinity for a natriuretic... Agent: University Of South Florida
20130330383 - Ocular drug delivery system: An ocular drug delivery system can include a composition in which a formulation including recombinant human growth hormone (rHGH) is contained in a polymer matrix. The composition is configured for placement in or on the eye of a subject, and provides controlled release of an amount of the rHGH to... Agent: I Therapeutics, LLC
20130330376 - Test of insulin as a drug to reduce restenosis of vessels: Methods, compositions, and devices for treating restenosis are described. In accord with the invention, a composition containing CTGF and insulin is applied to blood vessels and restenosis is reduced or prevented.... Agent: Wisconsin Alumni Research Foundation
20130330380 - Topical drug delivery using phosphatidylcholine: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.... Agent: Transdermal Biotechnology, Inc.
20130330385 - Uv-photo-protecting cosmetic composition: The present invention related to an UV-photo-protecting cosmetic composition, comprising: (a) at least one aqueous phase, (b) at least one fatty phase, (c) at least one micronized organic UV-screening agent, the mean particle size of said micronized particles ranging from 0.01 to 2 μm, and (d) at least one organomodified... Agent: Momentive Performance Materials Gmbh
20130330386 - Structure, synthesis, and applications for conjugated polyampholytes: The present disclosure provides novel polyampholyte compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various polyampholytes show antibacterial activity and may also demonstrate antiviral antifungal and/or antibiofilm activity.... Agent:
20130330387 - Antimicrobial lubricant compositions: Antimicrobial lubricant compositions are disclosed. The antimicrobial lubricant compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. The compositions include an oil lubricant. Representative lubricants may include polydimethyl siloxane, trifluoropropyl copolymer polysiloxane, and a copolymer of dimethylsiloxane and trifluoropropylmethylsiloxane. The compositions include rheology modifiers as... Agent: Becton, Dickinson And Company
20130330388 - Porous sphere-like objects, method to form same and uses thereof involvoing the treatment of fluids including anti-bacterial applications: A method and resulting structure are described for the production of refractory and insulative boards comprised of ceramic balls. Improved thermal, physical and mechanical properties are achieved as while also eliminating the safety and environmental impact of fibrous refractories. Also presented is an apparatus and method to remove bacteria and... Agent: Mattech, Inc.
20130330390 - Biobeneficial coating compositions and methods of making and using thereof: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.... Agent: Abbott Cardiovascular Systems Inc.
20130330391 - Cartilage material: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or... Agent: Vivex Biomedical Inc.
20130330392 - Polymers of fluorinated monomers and hydrocarbon monomers: It is provided an implantable device including a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.... Agent: Abbott Cardiovascular Systems Inc.
20130330393 - Polymers of fluorinated monomers and hydrocarbon monomers: It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.... Agent: Abbott Cardiovascular Systems Inc.
20130330389 - Ultrasound-triggerable agents for tissue engineering: The present invention is directed to compositions and methods for delivering a tissue scaffold comprising ultrasound-triggerable agents to an individual.... Agent: The Regents Of The University Of Michigan
20130330394 - Non-resorbable polymer composite implant materials: Composites, constructs and implants comprising a non-resorbable polymer, such as polyetheretherketone (PEEK), having structure of interconnected struts, which may be coralline. Composites may comprise a first phase comprising a ceramic; and a second phase comprising a non-resorbable polymer; wherein each of the first and second phases have an interconnected strut... Agent:
20130330395 - Tyrosine kinase microspheres: Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such... Agent:
20130330396 - Methods for the treatment of throat discomfort: The physiological cooling agent N-ethyl-2,2-diisopropylbutanamide exhibits a surprising selectivity for throat cooling over mouth cooling, especially when consumed in the form of a confection. Methods of treating throat discomfort using N-ethyl-2,2-diisopropylbutanamide are described. Also described are various confections that incorporate N-ethyl-2,2-diisopropylbutanamide, including hard candy confections, soft candy confections, and center-filled... Agent: Intercontinental Great Brands LLC
20130330397 - Wound care products with peracid compositions: Methods have been developed for incorporation of a peracid compound into or on wound application matrices, such as bandages or dressings, and other matrices which will favorably impact wound healing and help eliminate microbial infection. The peracid compound comprises a base compound that is metabolically pertinent to wound healing, the... Agent: Chd Bioscience, Inc.
20130330402 - Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases: This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into... Agent:
20130330403 - Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation... Agent: Thomas Jefferson University
20130330401 - Lipids for therapeutic agent delivery formulations: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.... Agent: Nitto Denko Corporation
20130330398 - Method of making small liposomes: Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate... Agent:
20130330399 - Nanoparticle-based tumor-targeted drug delivery: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles... Agent:
20130330400 - Systems for treating pulmonary infections: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of... Agent: Insmed Incorporated
20130330404 - Extended release composition containing tramadol: An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma... Agent: Galephar Pharmaceutical Research, Inc.
20130330405 - Method of making a soft gel capsule comprising coq-10 solubilized in a monoterpene: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.... Agent: Soft Gel Technologies, Inc.
20130330406 - Bilayer tablet formulations: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of... Agent: Bristol-myers Squibb Company
20130330407 - Oral formulations and lipophilic salts of methylnaltrexone: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.... Agent: Wyeth, LLC
20130330408 - Solid particulate compositions comprising coenzyme q10: The present invention generally relates to improvements in the bioavailability and/or solubility of coenzyme Q10. For example, the present invention relates to methods for preparing particulate compositions including coenzyme Q10 that generally comprise dispersing and/or dissolving the coenzyme Q10 throughout a suitable solvent, and combining the coenzyme Q10 and an... Agent: Particle Dynamics International, LLC
20130330409 - Dosage form: The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a... Agent: Euro-celtique S.a.
20130330410 - Silica-coated calcium salt compositions: A composition including calcium salt and silica, wherein the silica is in the form of a silicate that is adsorbed onto the surface of the calcium salt, wherein the silica is not incorporated into the structure of the calcium salt, and wherein the composition is bioactive.... Agent: Novabone Products, LLC
20130330411 - Pharmaceutical cyclosporin compositions: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].... Agent: Sigmoid Pharma Limited
20130330412 - Smart polymeric nanoparticles which overcome multidrug resistance to cancer therapeutics and treatment-related systemic toxicity: Polymeric nanoparticles with a hydrophobic core that encapsulates curcumin and a hydrophilic shell with one or more chemotherapeutic agents (e.g., doxorubicin) associated with the shell surface are formed from N-isopropylacryl amide (NEPAAM), acrylic acid (AA), and at least one vinyl monomer selected from the group consisting of vinyl acetate, 4-vinyl... Agent: The Johns Hopkins University
20130330415 - Method of obtaining viable small tissue particles and use for tissue repair: The invention provides a composition including isolated small living tissue particles, a method of making the tissue particles, and a method of using the composition to ameliorate a tissue defect. The tissue particles are composed of cells and their associated extracellular molecules and are sized, in certain embodiments, to be... Agent: Zimmer Orthobiologics, Inc.
20130330414 - Methods and compositions for treating inflammation: This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.... Agent: Uti Limited Partnership
20130330413 - Nutritional compositions comprising chitin microparticles: Nutritional oral compositions are disclosed that contain a nutritional component, such as a macronutrient or a micronutrient. The nutritional compositions also include a chitin microparticle preparation preferably obtained by microfluidisation, wherein the chitin microparticles have an average diameter of between 1 and 100 μm.... Agent: Cmp Therapeutics Limited
20130330416 - Styptic storage and delivery: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or... Agent:
20130330417 - Nanocellulose foam containing active ingredients: Nanocellulose foams containing at least one active ingredient and methods of preparing such nanocellulose foams containing one or more active ingredients are provided herein. In some embodiments, a method for preparing nanocellulose foam containing active ingredients may include forming a liquid mixture of nanocellulose, wherein the nanocellulose is at least... Agent:
20130330418 - Natural silver disinfectant compositions: An antimicrobial composition contains a soluble silver salt and an alkanolamine or aminoalcohol. The composition may additionally contain an amino acid or amino acid salt and surfactant. The composition has additional stability and activity compared to prior art silver complexes.... Agent: The Clorox Company
20130330419 - Compositions and methods for personal tumor profiling treatment: The present invention discloses therapeutic compositions and methods for treating a patient having a tumor disease. Methods, and dietary compositions thereof, for determining a diet regime for a patient with a tumor disease include the steps of: providing a sample of the patient; profiling at least one biochemical parameter of... Agent:
20130330420 - Animal lesion treatment and prevention formulations and methods: An illustrative embodiment of an animal lesion treatment and prevention formulation includes a quantity of water, at least one acid provided in the quantity of water and magnesium sulfate as acid/base buffer mixed in the quantity of water with the at least one acid. In some embodiments, an antimicrobial agent... Agent: Advanced Food Technologies, LLC
20130330421 - Combinations of therapeutic agents for treating melanoma: The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein... Agent: Vib Vzw
20130330422 - Methods for increasing insulin sensitivity and treating diabetes with a bioactive chromium binding peptide: Disclosed are methods and compositions related to increasing insulin sensitivity and treating diabetes.... Agent: The Board Of Trustees Of The University Of Alabama
20130330423 - Composition to increase joint and/or postural stability: The invention is directed to a composition for the use to increase joint stability or postural stability, wherein said composition comprises branched chain amino acids. It is further directed to the use of branched chain amino acids for the preparation of a food supplement or medicament for the prophylaxis and/or... Agent: Merck Patent Gmbh
20130330424 - Non-medical increase or maintenance of body weight of a mammal: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least... Agent: N.v. Nutricia
20130330427 - Lip balm: A lip balm product having a synthetic ceramide, an anti-irritant compound, sodium hyaluronate, cosmetic wax, boswellic acids and/or esters and/or salts thereof, extract of the Portuluca pilosa plant, matrikin-mimetic peptide, dehydrated microspheres of marine collagen and glycosaminoglycans, and mica along with optional lip balm formulation acceptable carriers and/or solvents. Where... Agent:
20130330425 - Plant retinol formulations and associated method: Nutritional formulations and methods to produce safe vitamin A/retinol are described. In particular, methods and formulations containing plant pro-vitamin A carotenoids from momordica cochinchinensis spreng are disclosed. The formulations and associated method are characterized by high concentration of provitaminA carotenoids in a water soluble form with enhanced stability and absorption.... Agent:
20130330426 - Topical skin care formulations comprising plant extracts: Disclosed are compositions that include extracts from a Lonicera maackii and Polygonum hydropiper.... Agent: Mary Kay Inc.
20130330428 - Methods for treating neurological disorders using nutrient compositions: Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one... Agent:
20130330429 - Compositions and methods for treating depression: Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of... Agent: Alexander Vuckovic, M.d., LLC
20130330430 - Process for purifying guar: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the... Agent: Alcon Research, Ltd.
20130330431 - Olive juice extracts for promoting muscle health: Olive extracts comprising hydroxytyrosol are effective in promoting muscle health in both animals and humans which are subject to muscle damage, muscle pain and muscle soreness due to exercise. The olive extracts can decrease the accumulation of lactic acid present post-exercise, and can also work by maintaining glutathione levels.... Agent: DsmIPAssets B.v.
20130330432 - Uses of curculigo latifolia (c. latifolia) extracts: The present invention relates to Curculigo latifolia (C. latifolia) extracts, wherein the extracts extracted from different parts of a plant such as fruits, roots and leaves, individually and in any combinations thereof, characterized in that the extracts are used as an agent for treating and preventing metabolic disorder diseases such... Agent: Universiti Putra Malaysia12/05/2013 > 177 patent applications in 99 patent subcategories. patent applications/inventions, industry category
20130323165 - Magnetic nanoplatforms for theranostic and multi-modal imaging applications: Disclosed are nanoparticle compositions comprising paramagnetic particles, radiolabels, fluorophores, and/or positron emission tomography agents encapsulated within a biocompatible vehicle. In addition, methods of multi-modal diagnostic imaging and treating diseased tissues are disclosed, wherein the methods comprises administering a nanoparticle composition to a subject in which the nanoparticle composition comprises paramagnetic... Agent: Northeastern University
20130323168 - Agents and methods for visualizing analytes: Provided herein are novel compounds based on xanthene, for example biarsenical compounds, which are useful as molecular probes. The compounds contain at least one isotope atom, such as a radioisotope atom. Methods for visualizing tetracysteine-tagged analyte molecules such as proteins using said compounds, methods for synthesizing said compounds, and methods... Agent: Biopercept Ab
20130323167 - Detecting and treating solid tumors through selective disruption of tumor vasculature: Several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. Exemplary vascular-active agents include a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to... Agent: The Johns Hopkins University
20130323166 - Radiation therapy for treating alzheimer's disease: A method treating dementia of the Alzheimer's type in a patient by administering ionizing radiation to the brain of the patient.... Agent:
20130323169 - Thiol-ene click chemistry for drug conjugates: The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an autoimmune disease, an inflammatory condition, a central nervous system disorder or an infection. The linker inker molecules of the... Agent:
20130323170 - Prosthetic groups attached to stannyl polymer in the synthesis of radiopharmaceuticals: The present invention relates to compositions and methods for preparing radiopharmaceutical compounds in high chemical-purity and isotopic-purity. The present invention provides polymer-bound precursors to radiopharmaceutical compounds that can be converted to radiopharmaceutical compounds in one step. In a preferred embodiment, a radiopharmaceutical precursor is bound to a polymeric support via... Agent:
20130323171 - Radiolabeled bbn analogs for pet imaging of gastrin-releasing peptide receptors: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) of prostate cancer (PCa). RM1 and AMBA have been identified as the two most promising... Agent:
20130323172 - Molecular probes for multimodality imaging of anionic membrane surfaces: Embodiments provide dual modality probes for imaging phosphatidylserine (PS) exposure and other anionic membrane surfaces. In various embodiments, the probes were constructed by utilizing a) the high selectivity of synthetic zinc (II) dipicolylamine coordination complexes (Zn-DPA) for targeting externalized PS which over-expresses in apoptotic and necrotic cells, b) a near-infrared... Agent:
20130323173 - Antibodies to tumor endothelial marker 8: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods... Agent: The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt
20130323174 - Methods of detecting pancreobiliary ductal leaks: The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the... Agent:
20130323176 - Galectin-9-secreting cell, and production method and use of the same: The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed... Agent:
20130323175 - Use of 31p nmr spectroscopy of whole heart energetics for detection of drug-induced cardiotoxicity: Disclosed are methods of determining cardiac toxicity of a compound of interest, wherein a heart or cardiac cell of a mammal may be contacted a compound of interest and peak levels of one or more indicators of cardiac energetics after administration of the compound may be detected using 31P NMR... Agent: Battelle Memorial Institute
20130323182 - Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same: The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (MRI) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials,... Agent: Hanwha Chemical Corporation
20130323181 - Stabilized formulations containing iodinated contrast agents and cyclodextrins: The invention encompasses compositions containing an iodinated contrast agent and a substituted cyclodextrin wherein the cyclodextrin stabilizes the contrast agent against degradation by ultraviolet or visible light exposure.... Agent: Verrow Pharmaceuticals, Inc.
20130323178 - Indocyanine green-containing particle and contrast agent for photoacoustic imaging having the particle: Provided is the following indocyanine green (ICG)-containing particle to be used as, for example, a contrast agent for fluorescent imaging or photoacoustic imaging. The leakage of ICG from the particle in a serum is prevented and hence the particle can stably retain ICG. According to a particle characterized by having... Agent: Canon Kabushiki Kaisha
20130323177 - Tumor-targeting gas-generating nanoparticle, method for preparing the same, and tumor-targeting nanoparticle for drug delivery using the same: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating... Agent:
20130323180 - Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the... Agent: Hoffmann-la Roche Inc.
20130323179 - Nanocrystals, compositions, and methods that aid particle transport in mucus: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles... Agent: Johns Hopkins University, The
20130323183 - Absorbent dressings with painkilling activity: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The... Agent: Fidia Farmaceutici S.p.a.
20130323184 - Method of providing fast relief to a user of a nicotine chewing gum: The invention relates to a method of relieving nicotine craving comprising the steps of providing at least one chewing gum comprising tobacco alkaloid to a user, providing relief of nicotine craving to said user by transferring of tobacco alkaloid from the chewing gum to the human body of said user... Agent:
20130323185 - Methods of analyzing plaque: The invention provides a method of measuring ammonia and/or calcium in a sample of dental plaque, comprising obtaining the sample of plaque and measuring ammonium and calcium ions using capillary electrophoresis, together with methods of diagnosis, treatment and screening based on evaluation of plaque.... Agent: Colgate-palmolive Company
20130323186 - Dentifrice composition: A dentifrice, such as toothpaste, containing chitosan or pharmaceutically acceptable acid addition salt thereof with fluoride ions, for use against erosive tooth demineralization, and kits containing chitosan or pharmaceutically acceptable acid addition salt thereof with fluoride ions, wherein one of the two active agents is comprised in a dentifrice, are... Agent: Gaba International Holding Ag
20130323187 - Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.... Agent: Partnership & Corp. Technology Transfer
20130323188 - Water soluble fullerene formulations and methods of use thereof: The present invention provides water soluble fullerene formulations and methods of use thereof.... Agent: Board Of The Regents Of The University Of Nebraska
20130323189 - Antifungal nail coat and method of use: Antifungal nail coat compositions containing an allylamine, an N,N-di(C1-C8) alkylamino substituted, (C4-C18) alkyl (C2-C18) carboxylic ester or a pharmaceutically acceptable acid addition salt thereof, a hydrophilic polymer, and a pharmaceutically acceptable, volatile organic carrier are disclosed. The composition provides a substantially water-soluble, fungicidal coating upon contact with a fungally susceptible... Agent: Apricus Biosciences, Inc
20130323190 - Composition generating hydrogen: t
20130323192 - Base makeup cosmetic and method for producing the same: Provided are a method of producing a base makeup cosmetic, which includes mixing a solvent and a cosmetic base material including a red composite powder having a composite structure in which red pigment selected from the group consisting of lithol rubine B and lithol rubine BCA is intercalated into an... Agent: Fujifilm Corporation
20130323191 - Cosmetic products for reducing hair appearance: A cosmetic product for reducing the appearance of hair. The cosmetic product includes a composition made with at least one film forming polymer present in an amount sufficient to reduce the appearance of hair on a skin surface, and a dermatologically acceptable carrier. The product also includes indicia that communicates... Agent: The Procter & Gamble Company
20130323193 - Oil-soluble deodorant composition and method for deodorizing ammonia odor and amine odor: The present invention provides an oil-soluble deodorant composition that is highly safe, efficienctly eliminates odors of ammonia, amines and the like and is free of an irritant odor and the like. The present invention relates to an oil-soluble deodorant composition containing at least one of a dimer acids and a... Agent: Takasago International Corporation
20130323194 - Method of eliminating cat urine odor: A method of eliminating cat urine odor. A CO2 generating mixture of carboxylic acid and a base is placed into a container and cat litter that is comprised of an absorbent material is placed over the top. During the deodorizing process of the cat urine, carbon dioxide is generated to... Agent: Co2 Technologies, Inc.
20130323195 - Hydrogel fibres and fibrous structures: A plurality of fibers or one-dimensional, two-dimensional, or three-dimensional fibrous structures are provided, having fibers from a first raw fiber material. The first raw fiber material contains unsubstituted or partially substituted polyvinyl alcohol and/or unsubstituted or partially substituted polyvinyl alcohol copolymer. The fibers can be crosslinked by tempering the fibers... Agent: Carl Freudenberg Kg
20130323199 - Collagen material and method for producing collagen material: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired... Agent: Atree, Inc.
20130323197 - Ifg-1 dependent modulation of vsels: Characteristics of the VSELs stem cell population of a mammal are correlated with aging, including VSEL number, imprinting status of genetic loci, and expression of markers of pluripotent stem cells. The present invention provides VSEL-based methods and compositions for determining the biological age of a mammal.... Agent: University Of Louisville Research Foundation, Inc.
20130323196 - Method for mobilizing stem and/or progenitor cells: The present disclosure relates to methods for mobilizing stem and/or progenitor cells which are VLA-4 positive to the peripheral blood of a subject or from a tissue. The method comprises administering to the subject or tissue an effective amount of an antisense compound to VLA-4.... Agent: Antisense Thereapeutics Ltd
20130323198 - Use of amg 900 for the treatment of cancer: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.... Agent:
20130323201 - Combination treatments and compositions for wound healing: Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.... Agent:
20130323200 - Gelsolin enrichment of blood samples using gold particles: In the method for producing at least one therapeutically effective protein or a protein mixture in a container, the container is filled with a body fluid and gold particles and incubated, and in this process the therapeutically effective protein is formed in the body fluid.... Agent: Arthrogen Gmbh
20130323202 - Methods of treating ocular and other diseases with syn-134r polypeptide: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.... Agent: Allergan, Inc.
20130323203 - Inhibitors of flaviviridae viruses: s
20130323204 - Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy: The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety.... Agent: Ibc Pharmaceuticals, Inc.
20130323206 - Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence: The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical... Agent: Industry-university Cooperation Foundation Hanyang University
20130323205 - Oncolytic adenoviral vectors and methods and uses related thereto: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a... Agent: Oncos Therapeutics Oy
20130323207 - Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders: The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as... Agent: Nationwide Children's Hospital, Inc.
20130323214 - Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies: The present invention concerns methods and compositions related to T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In aspects of the invention, T cells that are CD70-specific are employed. In particular aspects, there are T cells expressing a novel molecule that comprises the full-length CD70 receptor (CD27)... Agent:
20130323208 - Mycobacterium brumae cell wall extracts that can be used in therapy of superficial bladder cancer: Invention is using M. brumae is a mycobacterium strain which stimulates immune system cells strongly, is non-pathogen for humans and has all of the defining attributes of the strain with catalog number 51384, American Type Culture Collection (ATCC) for therapy of superficial bladder cancers.... Agent:
20130323216 - Synbiotic mixture: This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic Lactobacillus sp. The invention extends to nutritional compositions comprising said preparation and to the use of the preparation in the prevention and treatment of pathogenic infections of the gastro-intestinal and upper respiratory tracts.... Agent: Nestec S.a.
20130323215 - Tumour cytotoxic agent and methods thereof: The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium.... Agent:
20130323218 - Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads: Methods are provided for selecting a bacterium capable of reducing pathogenic bacterial colonization of the intestinal tract in a subject comprising selecting the bacterium capable of migrating at least 0.75 cm from the point of inoculation on motility agar after incubation for 24 hours at 37° C. or capable of... Agent: The Board Of Trustees Of The University Of Arkansas
20130323217 - Compositions and methods for the controlled repopulation of gram-negative bacteria in the colon: The present invention relates to a method for the controlled repopulation of the colonic bacterial flora.... Agent: Universite Paris Diderot-paris 7
20130323210 - Infectious schmallenberg virus from cloned cdnas and uses thereof: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious Schmallenberg virus (SBV) useful for studying viremia and diseases caused by SBV in ruminants, and in the development of vaccines, therapeutics and diagnostics for the... Agent: Boehringer Ingelheim Vetmedica Gmbh
20130323209 - Novel bacteriophage and its use for preventing proliferation of pathogenic bacteria: The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a... Agent: Ctc Bio, Inc.
20130323213 - Adherent cells from adipose or placenta tissues and use thereof in therapy: A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A... Agent: Pluristem Ltd.
20130323211 - Short rna molecules: The present invention provides a short RNA capable of upregulating MafA expression in a human cell, wherein said short RNA includes a first strand which is 19 to 25 nucleotides in length and comprises the sequence AUCUGUACUGGAUGAGCGG or UUUCCCGCAGGAGAUUGAC. Also provided are uses thereof, particular medical uses, and induced cells... Agent: Mina Therapeutics Limited
20130323212 - Treatment for chronic myocardial infarct: A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).... Agent: Biocardia, Inc.
20130323219 - Composition comprising a combination of at least one proteolytic enzyme and at least one lipolytic enzyme, for use in preventing triglyceride synthesis: The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use... Agent: Imarko Research S.a.
20130323223 - Methods of treating celiac disease: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate... Agent: Curemark, LLC
20130323222 - Human tissue kallikrein 1 glycosylation isoforms: Provided are preparations of tissue kallikrein-1 (KLK1) glycoforms having a defined number of oligosaccharide units per KLK1 molecule. Also provided are mixtures of such glycoforms, pharmaceutical compositions containing such glycoforms or mixtures thereof, methods of obtaining the rhKLK1 glycoforms, and therapeutic uses thereof... Agent:
20130323221 - Plant lectins as carriers of associated drug substances into animal and human cells: The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate... Agent: Biostrategies Lc
20130323220 - Tal-tet1 fusion proteins and methods of use thereof: Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines in DNA, and methods of use thereof.... Agent: The General Hospital Corporation
20130323225 - Broccoli based nutritional supplements: A nutritional supplement is provided containing two broccoli based components that are combined and, when ingested, react in the intestines to provide sulforaphane. Processes for producing the broccoli components of the nutritional supplement are also provided. The broccoli components are treated separately using supercritical fluid extraction to remove oils. The... Agent:
20130323226 - Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer: A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and... Agent: The Trustees Of The University Of Pennsylvania
20130323224 - Use of mycobacterium smegmatis trehalose dimycolate hydrolase: Methods are disclosed herein for treating an infection with a Mycobacterium infection. Methods are also disclosed for treating a Mycobacterium biofilm. The method include the use of trehalose dimycolate hydrolase, a variant thereof, or a nucleic acid encoding trehalose dimycolate hydrolase or a variant thereof. Methods are also disclosed for... Agent:
20130323227 - Pharmaceutical compositions of tenecteplase: Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is... Agent: Gennova Biopharmaceuticals Limited
20130323228 - Cleansing and anti-acne composition: Disclosed is a cleansing composition and methods for its use capable of treating acne comprising an anti-acne agent comprising benzoyl peroxide, a combination of cleansing agents comprising disodium laureth sulfosuccinate and sodium C14-16 olefin sulfonate, and a combination of skin active ingredients comprising Cucurbita pepo fruit extract, niacinamide, epilobium angustifolium... Agent:
20130323229 - Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid: The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of... Agent: University Of Medicine And Dentistry Of New Jersey
20130323231 - Treatment and prognosis of solid tumour cancers: The invention is based on the finding that the human RPT4 protein/gene can function as a therapeutic target for solid tumour type cancers, especially solid tumours of the colon, and that reducing the abundance of RPT4 in tumour cells causes a significant increase in cancer cell death, and potently decreases... Agent: Royal College Of Surgeons In Ireland
20130323230 - Treatment of myelosuppression: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.... Agent: Paringenix, Inc.
20130323238 - Antagonists of il-6 to raise albumin and/or lower crip: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an... Agent:
20130323236 - Antibodies of the class igg4: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted... Agent: Ucb Pharma S.a.
20130323240 - Humanized antibodies against light and uses thereof: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease;... Agent: Teva Biopharmaceuticals Usa, Inc.
20130323233 - Materials and methods for improved immunoglycoproteins: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.... Agent:
20130323232 - Methods for the identification and treatment of patients sensitive to anti igf-1r inhbition therapy: Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment... Agent:
20130323239 - Modulation of pilr receptors to treat sepsis: The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILRα and PILRβ, respectively, to prevent the development of sepsis.... Agent: Merck Sharp & Dohme Corp.
20130323234 - Mutant antibodies and conjugation thereof: The present invention relates to a polypeptide comprising 7 β-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first α-helix sequentially located on the EF chain between β-strands E and F, wherein the β-strands are arranged so as to... Agent: Covx Technologies Ireland Limited
20130323237 - Organic compounds: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.... Agent:
20130323235 - Soluble heavy-chain only antibodies: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present... Agent: Erasmus University Medical Center
20130323241 - Treatment of angiogenesis disorders: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.... Agent: Rockefeller University (the)
20130323245 - Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.... Agent: Morehouse School Of Medicine
20130323244 - Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides... Agent: Alexion Pharma International Sarl
20130323242 - Compositions comprising an anti-pdgf aptamer and a vegf antagonist: The present invention is directed to compositions comprising an anti-PDGF aptamer and a VEGF antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease.... Agent: Ophthotech Corp.
20130323243 - Filovirus fusion proteins and their uses: This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Dept Of Hhs
20130323246 - Use of mdl-1 antagonists to treat spondylarthropathy: The invention provides methods for treating spondylarthropathy with antagonists of MDL-1 alone or in combination with IL-23 antagonists.... Agent: Merck Sharp & Dohme Corp.
20130323248 - Antigen binding proteins that bind dll-4: There is disclosed compositions and methods relating to or derived from anti-DLL-4 antibodies. More specifically, there is disclosed fully human antibodies that bind DLL-4, DLL-4-binding fragments and derivatives of such antibodies, and DLL-4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and... Agent: Sorrento Therapeutics Inc.
20130323249 - Antigen binding proteins that bind pd-l1: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and... Agent: Sorrento Therapeutics Inc.
20130323247 - Treatment of acute lymphoblastic leukemia: The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.... Agent: Micromet Ag
20130323250 - Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on... Agent:
20130323251 - Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.... Agent: Merck Sharp & Dohme Corp.
20130323257 - Antibodies that bind the glutamate ligand binding region of notch3: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.... Agent: Oncomed Pharmaceuticals, Inc.
20130323258 - Compositions and methods for treating cardivascular disease: The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40... Agent: Amgen Inc.
20130323259 - Il-21 ligands: The present invention relates to IL-21 ligands binding to a discontinuous epitope on the surface of the IL-21 molecule as well as use thereof.... Agent: Novo Nordisk A/s
20130323252 - Molecules and methods for modulating tmem16a activities: The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.... Agent: Novartis Ag
20130323256 - S. agalactiae antigens i + ii: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.... Agent: Intercell Ag
20130323255 - Serum mg53 as a diagnostic marker for tissue injury: Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood... Agent:
20130323254 - Therapeutic anti-tirc7 antibodies for use in immune related and other diseases: Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided.... Agent:
20130323253 - Xyxin fragment biomarker for diagnosis of colon cancer: The present invention relates to the field of the diagnosis of large intestine/colon diseases. More particularly, the present invention provides a method for differential diagnosis of colorectal cancer from a non-malignant disease of the large intestine/colon, and from a healthy large intestine/colon. The invention also relates to treatment of colorectal... Agent: Miraculins, Inc.
20130323261 - Purified antibody composition: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.... Agent:
20130323260 - Stabilized formulations containing anti-dll4 antibodies: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree... Agent: Regeneron Pharmaceuticals, Inc.
20130323262 - Methods and materials for treating inflammatory conditions: Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity.... Agent: Mayo Foundation For Medical Education And Research
20130323264 - Diagnostic and therapeutic uses of moesin fragments: The present application provides compositions and methods for modulating the activity and quantity of platelets and preventing and treating disorders or diseases associated with abnormal activity and quantity of platelets.... Agent: Shanghai Kexin Biotech Co., Ltd.
20130323265 - Methods for treating cancer with dll4 antagonists: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.... Agent: Oncomed Pharmaceuticals, Inc.
20130323266 - Methods for treating cancer with notch2/3 antibodies: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a Notch2/3 antibody.... Agent: Oncomed Pharmaceuticals, Inc.
20130323263 - Sparc angiogenic domain and methods of use: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.... Agent: Abraxis Bioscience, LLC
20130323267 - Highly concentrated anti-cd40 antibody pharmaceutical preparation: The present invention relates to a highly concentrated solution preparation of antagonistic anti-CD40 antibody, in which occurrence of turbidity or insoluble foreign matter attributed to antibodies is suppressed to a level equivalent to that of the conventional low-concentration lyophilized preparation.... Agent: Kyowa Hakko Kirin Co., Ltd.
20130323268 - Cytotoxic agents comprising new ansamitocin derivatives: New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These... Agent: Immunogen, Inc.
20130323270 - Cyclosporine emulsion: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment... Agent: Neurovive Pharmaceutical Ab
20130323269 - Methods and compositions for delivery of active agents: A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an... Agent:
20130323271 - Nitric oxide donor neprilysin inhibitors: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such... Agent:
20130323272 - Novel and powerful mhc-class ii peptides derived from survivin: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate... Agent: Immatics Biotechnologies Gmbh
20130323273 - Adipogenic adenoviruses as a biomarker for disease: A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject.... Agent: Obetech, LLC
20130323274 - Escherichia coli immunogens with improved solubility: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.... Agent: Novartis Ag
20130323276 - Malaria vaccines based on pre-erythrocytic antigens from p. falciparum: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides... Agent: Ruprecht-karls-universitÄ T Heidelberg
20130323275 - Methods and compositions for inducing a t-cell response to plasmodium species: The present invention relates to methods of inducing a T-cell response against a Plasmodium species antigen in a subject. These method comprise administering to a subject a composition comprising a bacterium which expresses one or more immunogenic polypeptides, the amino acid sequence of which comprise one or more amino acid... Agent: Aduro Biotech
20130323277 - Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof: The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn... Agent: Boehringer Ingelheim Vetmedica Gmbh
20130323278 - Chimeric flavivirus vaccines: A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E... Agent:
20130323279 - Human endogenous retrovirus polypeptide compositions and methods of use thereof: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide.... Agent: The Governing Counicl Of University Of Toronto
20130323280 - Methods for preparing vesicles and formulations produced therefrom: The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of vesicle-forming lipids to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed, wherein in the step of adding the molten... Agent: Variation Biotechnologies, Inc.
20130323281 - Ordered flagellin array as an immunostimulant: Bacterial flagellin protein is modified to improve adjuvant activity.... Agent:
20130323282 - Compositions and methods: The present invention provides a composition comprising hepatitis C virus (HCV) Envelope 2 (E2) glycoprotein, wherein the HCV E2 is substantially monomer depleted HCV E2. Also provide are methods of inducing an HCV immune response.... Agent:
20130323283 - Compositions and methods for treating foxp3+ treg related diseases: Methods for treating or preventing a Foxp3+ T regulatory cell (Treg) related disease in a subject in need thereof comprise administering to the subject an effective amount of a pharmaceutical composition comprising an inhibitor of a histone/protein acetyltransferase (HAT). Methods for identifying an agent useful for treating or preventing a... Agent: The Trustees Of The University Of Pennsylvania
20130323285 - Peptide adjuvants: Adjuvant compositions comprising specific 5mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.... Agent:
20130323284 - Use of mtor inhibitors to treat bacterial infection: A method for treating a mammal having an infection with an organism that persists intracellularly in a mammalian cell by inducing an autophagy defect includes administering to the mammal an effective dose of a bioavailable agent that restores autophagy function, by inhibition of the mTOR pathway.... Agent: Jazzya Investments
20130323289 - Antimicrobial substance, method for producing same, and antimicrobial material: Provided an antimicrobial substance that includes a base material layer, and a copper-tin alloy layer 5-200 nm in thickness disposed on the base material layer, the copper-tin alloy layer containing copper in an amount of more than 60 atomic percent but not more than 90 atomic percent, and containing tin... Agent: Mitsui Chemicals, Inc.
20130323287 - Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the... Agent: Jds Therapeutics, LLC
20130323288 - Pharmaceutical formulation for bedwetting and method of use thereof: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.... Agent: Wellesley Pharmaceuticals, LLC
20130323286 - Synthesis of r-n-methylnaltrexone: This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.... Agent: Progenics Pharmaceuticals, Inc.
20130323290 - Antitoxic fibers and fibrous media and methods for manufacturing same: Antitoxic fibers and fibrous media contain impregnated material including an antitoxin. A method for producing antitoxic fibers and fibrous media includes impregnating a fibrous media by dipping in a dipping solution containing a concentrate of an antitoxin to form a fiber with impregnated material including an antitoxin. The impregnated material... Agent:
20130323291 - Hydrophilic and non-thrombogenic polymer for coating of medical devices: A hydrophilic copolymer is designed and synthesized by copolymerization of an acidic monomer and a second hydrophilic monomer. The copolymer is non-thrombogenic, hydrophilic and incorporates reactive functional groups. The copolymer can then be covalently attached to a primer/base coat through its functional groups, to form a durable lubricious coating on... Agent: Biocoat Incorporated
20130323292 - Clog resistant insect control formulations containing pyrethrin, an acetylenic compound, and a hydrocarbon diene: Disclosed are pyrethrin-based insect control formulations which have been formulated to reduce wick clogging in dispensers which use heaters to drive an insect control active from the wick. Pyrethrum extract is mixed with an acetylenic compound, such as prallethrin or 3,5-dimethylhex-1-yn-3-ol, and a terminal diene compound such as myrcene or... Agent:
20130323293 - Glp-1 analogue composition for microneedle devices: A GLP-1 analogue composition for a microneedle device, including a GLP-1 analogue and at least one kind of solvent selected from the group consisting of water, glycerin, propylene glycol, ethylene glycol, 1,3-butylene glycol, and polyethylene glycol.... Agent:
20130323294 - Tissue repair and replacement: Tissue fixation devices are provided. The devices include a first component and a second component, the components having different rates of in vivo degradation. The first component and second component are arranged so that, upon degradation of one of the components, the other component provides a scaffold into which bone... Agent: Smith & Nephew, Inc.
20130323295 - Monomer systems with dispersed silicone-based engineered particles: Provided are compositions containing engineered particles, and methods of making such engineered particles. Polymeric articles, such as contact lenses, prepared from such compositions are also provided. Such engineered particles are dispersible in hydrophilic systems such as monomer systems for preparation of contact lenses. Each of the engineered particles comprises a... Agent: Johnson & Johnson Vision Care, Inc.
20130323296 - Carrier for oromucosal, especially sublingual administration of physiologically active substances: The present disclosure relates to a carrier for oromucosal, especially sublingual administration of physiologically active substances, especially of medicinal drugs, which consists of at least one elastic layer (1) of polymer nanofibres workable according to the shape of the selected wall of mouth cavity to which it should be applied... Agent:
20130323297 - Local administration of gallium compositions to treat pain: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together... Agent:
20130323298 - Amphoteric liposome formulation: The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.... Agent: Pronai Therapeutics, Inc.
20130323301 - Enhanced cancer treatment and monitoring using recombinant vectors: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression... Agent: Tocagen Inc.
20130323299 - Method of inducing neutralizing antibodies to human immunodeficiency virus: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.... Agent:
20130323300 - Therapeutic composition for treatment of glioblastoma: The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).... Agent: Regents Of The University Of Minnesota
20130323302 - Treatment of amd using aav sflt-1: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human... Agent: Avalanche Australia Pty Ltd.
20130323303 - Drug carrier and preparation method thereof: A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid. The components of the aqueous micelles are phospholipids and amphiphilic chitosan, and the aqueous micelles enclose an aqueous solution containing a... Agent: National Chiao Tung University
20130323304 - Methods for enhancing the release and absorption of water insoluble active agents: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The... Agent: Banner Pharmacaps, Inc.
20130323305 - Compositions and methods comprising energy absorbing materials for follicular delivery: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20... Agent: The General Hospital Corporation
20130323306 - Injectable biodegradable particles for controlled therapeutic agent release: In accordance with one aspect, embolic particles are provided that comprise a biodegradable polymer and a therapeutic agent, wherein the particles are configured such that, upon administration to a body lumen of a subject, the therapeutic agent is released from the time of administration up until a first point in... Agent: Boston Scientific Scimed, Inc.
20130323307 - Sildenafil-free base-containing film preparation and method for producing same: The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil... Agent: Ctc Bio, Inc.
20130323308 - Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of... Agent:
20130323309 - Sustained release composition of memantine: A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance... Agent: Lupin Limited
20130323311 - Collagen-targeted nanoparticles: This invention relates to compositions comprising collagen binding peptides coupled to nanoparticles. The invention also relates to a method of imaging a collagenous matrix using a composition comprising collagen binding peptides coupled to nanoparticles.... Agent: Purdue Research Foundation
20130323310 - Swellable particles for drug delivery: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 μm, the particles being swellable by hydration to a size that... Agent: Stc.unm
20130323312 - Microspheres including oxidized cellulose: A process for forming microspheres is disclosed. The process includes: forming a first plurality microspheres comprising at least one bioactive agent and modified cellulose; contacting the first plurality of microspheres with a solution of a biodegradable polymer to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a... Agent: Confluent Surgical, Inc.
20130323313 - Mucus penetrating gene carriers: Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle... Agent: The Johns Hopkins University
20130323317 - Injectable and swellable microspheres for tissue bulking: The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.... Agent: Biosphere Medical, Inc.
20130323316 - Injectable microspheres for dermal augmentation and tissue bulking: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the... Agent: Biosphere Medical, Inc.
20130323315 - Microspheres including oxidized cellulose: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form... Agent: Confluent Surgical, Inc.
20130323314 - Novel nanoparticles of lactoferrin useful for preparing a pharmaceutical composition facilitating easy delivery of the drug and a process for preparing the same: Novel nanoparticles of lactoferrin useful for preparing a pharmaceutical composition facilitating easy delivery of the drug contained therein wherein the sizes are in diameter in the range of 40 to 90 nanometers.... Agent: University Of Hyderabad
20130323318 - Protein free surfactant composition for pulmonary diseases and a process for preparing the same: A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome.... Agent: Indian Institute Of Technology
20130323319 - Modified immune-modulating particles: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.... Agent: Getts Consulting And Project Management
20130323320 - Ph sensitive carrier and preparation method thereof, and ph sensitive drug and ph sensitive drug composition each containing the carrier, and method for treating or preventing diseases using the same: A pH sensitive carrier which includes at least one pH sensitive compound selected from the group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, C27 bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof, and at least one amphipathic substance selected from the group... Agent:
20130323322 - Method for making a gas from an aqueous fluid product of the method and apparatus therfor: A method for producing a purified, stable, compressible gas from an aqueous fluid. The gas is suitable for a variety of uses and may also be infused into water which itself is useful for a variety of purposes... Agent:
20130323321 - Personal hygiene composition, article of manufacture and method comprising chakra stone: Chakra stones or crystals are included as part of a personal hygiene or body cleansing composition as a novelty item or for aesthetic or decorative purposes. The chakra stones or crystals can also be used for their spiritual significance and for realigning, revitalizing, or balancing unbalanced chakra energies of the... Agent:
20130323323 - Therapeutic method and associated compound for augmenting the liver's metabolization of oxygen-modified toxins: A therapeutic method and associated composition for counteracting the negative and toxic physiological effects of the consumption or production of oxygen-modified toxins, such as alcohol, congeners, and associated metabolites, by augmenting or restoring the liver's ability to metabolize said elements, thereby preventing or abating the negative effects of the toxins,... Agent:
20130323324 - Vanadium and vanadyl amino acid complexes: Compositions that include vanadium or vanadyl chelated to an amino acid are disclosed, particularly vanadium or vanadyl chelated to creatine, arginine, citrulline, taurine, phenylalanine, glutamine, glutathione, leucine, or combinations thereof. In addition, compositions that included blended forms of such chelates and/or vanadyl sulfate and one or more unbound amino acids.... Agent:
20130323325 - Composition comprising mixed metal compounds and xanthan gum: The present invention provides a composition comprising (i) a mixed metal compound containing at least one trivalent metal selected from iron (lll) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, (ii) xanthan gum (iii) at least one of (a) polyvinyl... Agent: Cytochroma Development Inc.
20130323326 - Method for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition prepared on-site: A composition and method are described for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition. Fibrous adhesions typically form during healing of tissue, for example following a surgical procedure. A multicomponent oxychlorine composition is provided for irrigating the tissue which minimizes post-surgical adhesion formation, the composition... Agent:
20130323327 - Method for preventing nasolacrimal duct obstruction: The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer. The method includes administering an effective amount of perchlorate anion to the eyes of the patient.... Agent:
20130323328 - Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas: The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas.... Agent: Selo Medical Gmbh
20130323329 - Method of using rhein for treating fibrotic conditions and tumors: The present invention relates to a method of using an anthraquinone derivative namely 9,10-Dihyro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, or known as Rhein, for treating chronic pancreatitis induced fibrosis of the pancreas. More particularly, the present invention relates to a method of using Rhein, its derivatives and/or chemical variants as an anti-fibrotic agent. The... Agent: Hong Kong Baptist University
20130323330 - Methods for inhibiting prostate cancer by kinases and angiogenesis inhibitory mechanisms of ball moss extract: A method of treating prostate cancer by administering a pharmaceutically-acceptable amount of a crude extract of the indigenous Jamaican plant Ball Moss (Tillandsia Recurvata) comprising one or more cycloartane isolates, and the isolates used in the method for eliciting thereby a kinase inhibitory response of prostate cancer cells by selectively... Agent:
20130323331 - Pharmaceutical composition for preventing and treating inflamatory disease or asthma containing an extract of decaspermum fruticosum: The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract of Decaspermum fruticosum as an active ingredient. The extract of Decaspermum fruticosum of the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin-induced asthma... Agent: Korea Institute Of Oriental Medicine
20130323332 - Hand and body moisturizing serum: An organic hand and body moisturizing serum comprised of; Sacha Inchi seed oil, Camellia seed oil, Sunflower seed oil, Jojoba oil, Palm stearic acid flakes, an emulsifying wax, Vitamin E d-alpha tocopherol, Lecithin, Rosemary oil, Tea tree oil, and Helichrysum oil or Evening Primrose seed oil. Another embodiment of the... Agent:
20130323333 - Nourishing oil composition, pomade, composition for promoting hair growth, shampoo, conditioner, hair root stimulator, and methods for making and using the same: Compositions for promoting hair growth can be formed using food related oils. The food related oils include meadowfoam seed oil, neem oil, sesame oil, camelina, flaxeed oil, and tamanu oil. The oil can be combined with lime peel essential oil and/or aloe vera to create various products. The products in... Agent: Sayblee Handmade Natural Hair Care, LLC
20130323334 - Use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria: Compositions administered by topical route contain as active ingredients an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. A method for preventing, reducing... Agent: Legacy Healthcare Ltd.
20130323335 - Plant extracts for the treatment and prevention of infections: A composition comprising a Sanguisorbae officinalis plant extract and at least one additional plant extract selected from the group consisting of an Ailanthus altissima plant extract, a Galla rhois gallnut plant extract, a Glycyrrhiza Glabra plant extract, a Rheum palmatum plant extract and a Scutellaria baicalensis plant extract is disclosed.... Agent:
20130323336 - Method of increasing omega-3 content in poultry: A feed supplement for poultry consisting of distillers dried grains with solubles (DDGS) and flaxseed. The supplement is prepared using a dry extrusion process. Also described is a method of using the feed supplement to increase omega-3 fatty acids in poultry products, such as eggs.... Agent:
20130323337 - Novel herbal composition for the treatment of wound healing, a regenerative medicine: The present invention discloses a novel, synergistic, effective herbal composition as a regenerative medicine comprising combination therapeutically effective amounts of extracts obtained from Curcuma longa, Glycyrrhiza glabara, Hamiltonia suaveolens, Typha angustifolia and Azadirachta indica, along with optionally comprising Pig fat in Sesamum indicum (Til) oil as a base, useful for... Agent:
20130323338 - Control of insect pests: A bed lifting apparatus comprising a base and a support frame connected by at least one linkage arm, the at least one linkage arm including at least one biasing arrangement arranged to maintain the base and the support frame in a spaced apart relationship, wherein, in use, when a bed... Agent: Innovate Ag Pty Limited
20130323339 - Composition comprising banyan tree, lotus, and clover serum fractions (aging): The present invention relates to compositions comprising banyan tree, lotus, and clover serum fractions. A method of improving the appearance of aging skin may comprise the step of applying a composition comprising an effective amount of banyan tree serum fraction, lotus serum fraction, and clover serum fraction to a sign... Agent: Akzo Nobel Surface Chemistry LLC
20130323340 - Vegetable extract and method of use as an active principle in the production of a pharmacologically active product for the treatment of tissue lesions, and method for obtaining the extract: A resin extract from the Ficus pertusa L.f and/or Ficus eximia Schott tree and method of use as an active principle in the production of a pharmacologically active product for the treatment of acute and/or chronic tissue lesions in both bone tissue and soft tissue. A method for obtaining the... Agent:
20130323341 - Antiviral compositiion: The present invention relates to a composition comprising extract of the plant Ficus arnottiana. The invention also relates to a process for the preparation of the composition and to the composition for the use in the treatment of viral infections, particularly caused by herpes simplex viruses (HSV). The invention further... Agent: Piramal Enterprises LimitedPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20140227:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
Results in 3.72423 seconds